☰

Dominique Figarella-Branger - Publications

Affiliations: 
Aix Marseille 2 
Area:
Glioblastomas, Treatment, Proscillaridin A, Tumor location, Braf, pediatric brain tumors, molecular profil, DNT, low grade glioma, pilocytic astrocytoma, ganglioglioma, Tenascin R, Pilocytic astrocytomas, Extracellular matrix, Angiogenesis, Invasiveness
Tree Info Grants Similar researchers Related pubs Distance to... Nearest Nobel PubMed Report error

358 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Bastiancich C, Snacel-Fazy E, Fernandez S, Robert S, Stacchini R, Plantureux L, Boissonneau S, Testud B, Guillet B, Debarbieux F, Luche H, Figarella-Branger D, Estève MA, Tabouret E, Tchoghandjian A. Tailoring glioblastoma treatment based on longitudinal analysis of post-surgical tumor microenvironment. Journal of Experimental & Clinical Cancer Research : Cr. 43: 311. PMID 39605004 DOI: 10.1186/s13046-024-03231-4  0.771
2024 Métais A, Dangouloff-Ros V, Garcia J, Vannod-Michel Q, Csanyi M, Tauziède-Espariat A, Appay R, Maurage CA, Uro-Coste E, Meyronet D, Rigau V, Rousseau A, Chotard G, Hamelin J, Pierron G, ... ... Figarella-Branger D, et al. Phenotypic and epigenetic heterogeneity in FGFR2-fused glial and glioneuronal tumours. Neuropathology and Applied Neurobiology. 50: e13014. PMID 39511841 DOI: 10.1111/nan.13014  0.587
2024 Kacimi SEO, Dehais C, Feuvret L, Chinot O, Carpentier C, Bronnimann C, Vauleon E, Djelad A, Cohen-Jonathan Moyal E, Langlois O, Campone M, Ducloie M, Noel G, Cuzzubbo S, Taillandier L, ... ... Figarella-Branger D, et al. Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2400049. PMID 39356975 DOI: 10.1200/JCO.24.00049  0.547
2024 Snacel-Fazy E, Soubéran A, Grange M, Joseph K, Colin C, Morando P, Luche H, Pagano A, Brustlein S, Debarbieux F, Toutain S, Siret C, van de Pavert SA, Rougon G, Figarella-Branger D, et al. SMAC mimetic drives microglia phenotype and glioblastoma immune microenvironment. Cell Death & Disease. 15: 676. PMID 39278921 DOI: 10.1038/s41419-024-07056-z  0.794
2024 Soubéran A, Jiguet-Jiglaire C, Toutain S, Morando P, Baeza-Kallee N, Appay R, Boucard C, Graillon T, Meyer M, Farah K, Figarella-Branger D, Tabouret E, Tchoghandjian A. Brain tumoroids: treatment prediction and drug development for brain tumors with fast, reproducible and easy-to-use personalized models. Neuro-Oncology. PMID 39252580 DOI: 10.1093/neuonc/noae184  0.754
2024 Hein V, Baeza-Kallee N, Bertucci A, Colin C, Tchoghandjian A, Figarella-Branger D, Tabouret E. GD3 ganglioside is a promising therapeutic target for glioma patients. Neuro-Oncology Advances. 6: vdae038. PMID 38590763 DOI: 10.1093/noajnl/vdae038  0.814
2023 Harlay V, Appay R, Bequet C, Petrirena G, Campello C, Barrié M, Autran D, Graillon T, Boissonneau S, Dufour H, Figarella-Branger D, Padovani L, Barlier A, Nanni I, Tabouret E, et al. Radio-chemotherapy feasibility for biopsy-only unresectable wild-type glioblastomas (BO-GBM). Neuro-Oncology Practice. 10: 536-543. PMID 38009116 DOI: 10.1093/nop/npad028  0.681
2023 Ariey-Bonnet J, Berges R, Montero MP, Mouysset B, Piris P, Muller K, Pinna G, Failes TW, Arndt GM, Morando P, Baeza-Kallee N, Colin C, Chinot O, Braguer D, Morelli X, ... ... Figarella-Branger D, et al. Combination drug screen targeting glioblastoma core vulnerabilities reveals pharmacological synergisms. Ebiomedicine. 95: 104752. PMID 37572644 DOI: 10.1016/j.ebiom.2023.104752  0.673
2023 Baeza-Kallee N, Bergès R, Hein V, Cabaret S, Garcia J, Gros A, Tabouret E, Tchoghandjian A, Colin C, Figarella-Branger D. Deciphering the Action of Neuraminidase in Glioblastoma Models. International Journal of Molecular Sciences. 24. PMID 37511403 DOI: 10.3390/ijms241411645  0.796
2023 Appay R, Sarri B, Heuke S, Boissonneau S, Liu C, Dougy E, Daniel L, Scavarda D, Dufour H, Figarella-Branger D, Rigneault H. Live Stimulated Raman Histology for the Near-Instant Assessment of Central Nervous System Samples. The Journal of Physical Chemistry. B. PMID 37071666 DOI: 10.1021/acs.jpcb.3c01156  0.545
2023 Bikfalvi A, da Costa CA, Avril T, Barnier JV, Bauchet L, Brisson L, Cartron PF, Castel H, Chevet E, Chneiweiss H, Clavreul A, Constantin B, Coronas V, Daubon T, Dontenwill M, ... ... Figarella-Branger D, et al. Challenges in glioblastoma research: focus on the tumor microenvironment: (Trends in Cancer, 9:1 p:9-27, 2023). Trends in Cancer. PMID 36997420 DOI: 10.1016/j.trecan.2023.02.006  0.751
2023 Métais A, Tauziède-Espariat A, Garcia J, Appay R, Uro-Coste E, Meyronet D, Maurage CA, Vandenbos F, Rigau V, Chiforeanu DC, Pallud J, Senova S, Saffroy R, Colin C, Edjlali M, ... ... Figarella-Branger D, et al. Clinico-pathological and epigenetic heterogeneity of diffuse gliomas with FGFR3::TACC3 fusion. Acta Neuropathologica Communications. 11: 14. PMID 36647073 DOI: 10.1186/s40478-023-01506-z  0.602
2022 Keck MK, Sill M, Wittmann A, Joshi P, Stichel D, Beck P, Okonechnikow K, Sievers P, Wefers AK, Roncaroli F, Avula S, McCabe MG, Hayden JT, Wesseling P, Øra I, ... ... Figarella-Branger D, et al. Amplification of the PLAG-family genes-PLAGL1 and PLAGL2-is a key feature of the novel tumor type CNS embryonal tumor with PLAGL amplification. Acta Neuropathologica. PMID 36437415 DOI: 10.1007/s00401-022-02516-2  0.308
2022 Montégut C, Guillamo JS, Ducray F, Dehais C, Cohen-Jonathan Moyal E, Desenclos C, Petit A, Seizeur R, Bekaert L, Gaultier C, Motuo Fotso MJ, Blonski M, Frenel JS, Vauléon E, Langlois O, ... ... Figarella-Branger D, et al. Characteristics, Patterns of Care and Predictive Geriatric Factors in Elderly Patients Treated for High-Grade -Mutant Gliomas: A French POLA Network Study. Cancers. 14. PMID 36428602 DOI: 10.3390/cancers14225509  0.521
2022 Picart T, Poncet D, Barritault M, Bauchet L, Zouaoui S, Guyotat J, Gabut M, Fina F, Honnorat J, Figarella-Branger D, Pallud J, Ducray F, Meyronet D. Molecular Characterization of Adult Tumors Diagnosed as Cerebellar Glioblastomas Identifies Subgroups Associated With Prognosis. The American Journal of Surgical Pathology. 47: 131-144. PMID 36418240 DOI: 10.1097/PAS.0000000000001996  0.305
2022 Bikfalvi A, da Costa CA, Avril T, Barnier JV, Bauchet L, Brisson L, Cartron PF, Castel H, Chevet E, Chneiweiss H, Clavreul A, Constantin B, Coronas V, Daubon T, Dontenwill M, ... ... Figarella-Branger D, et al. Challenges in glioblastoma research: focus on the tumor microenvironment. Trends in Cancer. PMID 36400694 DOI: 10.1016/j.trecan.2022.09.005  0.772
2022 Catanzaro G, Besharat ZM, Carai A, Jäger N, Splendiani E, Colin C, Po A, Chiacchiarini M, Citarella A, Gianno F, Cacchione A, Miele E, Diomedi Camassei F, Gessi M, Massimi L, ... ... Figarella-Branger D, et al. MiR-1248: a new prognostic biomarker able to identify supratentorial hemispheric pediatric low-grade gliomas patients associated with progression. Biomarker Research. 10: 44. PMID 35715818 DOI: 10.1186/s40364-022-00389-x  0.6
2022 Figarella-Branger D, Colin C, Baeza-Kallee N, Tchoghandjian A. A2B5 Expression in Central Nervous System and Gliomas. International Journal of Molecular Sciences. 23. PMID 35563061 DOI: 10.3390/ijms23094670  0.785
2022 Appay R, Bielle F, Sievers P, Barets D, Fina F, Boutonnat J, Adam C, Gauchotte G, Godfraind C, Lhermitte B, Maurage CA, Meyronet D, Mokhtari K, Rousseau A, Tauziède-Espariat A, ... ... Figarella-Branger D, et al. Rosette-forming glioneuronal tumours are midline, FGFR1-mutated tumours. Neuropathology and Applied Neurobiology. e12813. PMID 35293634 DOI: 10.1111/nan.12813  0.596
2022 Chanez B, Appay R, Guille A, Lagarde A, Colin C, Adelaide J, Denicolai E, Jiguet-Jiglaire C, Bequet C, Graillon T, Boissonneau S, Nanni-Metellus I, Dufour H, Figarella-Branger D, Chinot O, et al. Genomic analysis of paired IDHwt glioblastomas reveals recurrent alterations of MPDZ at relapse after radiotherapy and chemotherapy. Journal of the Neurological Sciences. 436: 120207. PMID 35259554 DOI: 10.1016/j.jns.2022.120207  0.776
2022 Grimaldi S, Harlay V, Appay R, Bequet C, Petrirena G, Campello C, Barrié M, Autran D, Boissonneau S, Graillon T, Figarella-Branger D, Nanni I, Chinot O, Tabouret E. Adult H3K27M mutated thalamic glioma patients display a better prognosis than unmutated patients. Journal of Neuro-Oncology. 156: 615-623. PMID 34994963 DOI: 10.1007/s11060-022-03943-7  0.542
2022 Jiguet-Jiglaire C, Boissonneau S, Denicolai E, Hein V, Lasseur R, Garcia J, Romain S, Appay R, Graillon T, Mason W, Carpentier AF, Brandes AA, Ouafik L', Wick W, Baaziz A, ... ... Figarella-Branger D, et al. Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study. Acta Neuropathologica Communications. 10: 1. PMID 34980260 DOI: 10.1186/s40478-021-01305-4  0.789
2021 Figarella-Branger D, Appay R, Metais A, Tauziède-Espariat A, Colin C, Rousseau A, Varlet P. [The 2021 WHO classification of tumours of the central nervous system]. Annales De Pathologie. PMID 34865882 DOI: 10.1016/j.annpat.2021.11.005  0.64
2021 Pagano A, Breuzard G, Parat F, Tchoghandjian A, Figarella-Branger D, De Bessa TC, Garrouste F, Douence A, Barbier P, Kovacic H. Tau Regulates Glioblastoma Progression, 3D Cell Organization, Growth and Migration via the PI3K-AKT Axis. Cancers. 13. PMID 34830972 DOI: 10.3390/cancers13225818  0.667
2021 Métais A, Appay R, Pagès M, Gallardo C, Silva K, Siegfried A, Perbet R, Maurage CA, Scavarda D, Fina F, Uro-Coste E, Riffaud L, Colin C, Figarella-Branger D. Low-grade epilepsy-associated neuroepithelial tumours with a prominent oligodendroglioma-like component: the diagnostic challenges. Neuropathology and Applied Neurobiology. PMID 34551121 DOI: 10.1111/nan.12769  0.589
2021 Picart T, Barritault M, Poncet D, Berner LP, Izquierdo C, Tabouret E, Figarella-Branger D, Idbaïh A, Bielle F, Bourg V, Vandenbos FB, Moyal EC, Uro-Coste E, Guyotat J, Honnorat J, et al. Characteristics of diffuse hemispheric gliomas, H3 G34-mutant in adults. Neuro-Oncology Advances. 3: vdab061. PMID 34056608 DOI: 10.1093/noajnl/vdab061  0.535
2021 Pages M, Uro-Coste E, Colin C, Meyronet D, Gauchotte G, Maurage CA, Rousseau A, Godfraind C, Mokhtari K, Silva K, Figarella-Branger D, Varlet P, On Behalf Of The Renoclip-Loc Network. The Implementation of DNA Methylation Profiling into a Multistep Diagnostic Process in Pediatric Neuropathology: A 2-Year Real-World Experience by the French Neuropathology Network. Cancers. 13. PMID 33803647 DOI: 10.3390/cancers13061377  0.6
2021 Tabouret E, Fabbro M, Autran D, Hoang-Xuan K, Taillandier L, Ducray F, Barrie M, Sanson M, Kerr C, Cartalat-Carel S, Loundou A, Guillevin R, Mokhtari K, Figarella-Branger D, Delattre JY, et al. TEMOBIC: Phase II Trial of Neoadjuvant Chemotherapy for Unresectable Anaplastic Gliomas: An ANOCEF Study. The Oncologist. PMID 33783067 DOI: 10.1002/onco.13765  0.55
2021 Barets D, Appay R, Heinisch M, Battistella M, Bouvier C, Chotard G, Le Loarer F, Macagno N, Perbet R, Pissaloux D, Rousseau A, Tauziède-Espariat A, Varlet P, Vasiljevic A, Colin C, ... ... Figarella-Branger D, et al. Specific and Sensitive Diagnosis of -ITD in Various Cancers by Digital PCR. Frontiers in Oncology. 11: 645512. PMID 33718245 DOI: 10.3389/fonc.2021.645512  0.715
2021 Graillon T, Ferrer L, Siffre J, Sanson M, Peyre M, Peyrière H, Mougel G, Autran D, Tabouret E, Figarella-Branger D, Barlier A, Kalamarides M, Dufour H, Colin T, Chinot O. Role of 3-D volume growth rate for drug activity evaluation in meningioma clinical trials: the example of the CEVOREM study. Neuro-Oncology. PMID 33556177 DOI: 10.1093/neuonc/noab019  0.505
2020 Appay R, Fina F, Barets D, Gallardo C, Nanni-Metellus I, Scavarda D, Henaff D, Vincent J, Grewis L, Pourquier P, Colin C, Figarella-Branger D. Multiplexed Droplet Digital PCR Assays for the Simultaneous Screening of Major Genetic Alterations in Tumors of the Central Nervous System. Frontiers in Oncology. 10: 579762. PMID 33282733 DOI: 10.3389/fonc.2020.579762  0.617
2020 Argüello RJ, Combes AJ, Char R, Gigan JP, Baaziz AI, Bousiquot E, Camosseto V, Samad B, Tsui J, Yan P, Boissonneau S, Figarella-Branger D, Gatti E, Tabouret E, Krummel MF, et al. SCENITH: A Flow Cytometry-Based Method to Functionally Profile Energy Metabolism with Single-Cell Resolution. Cell Metabolism. 32: 1063-1075.e7. PMID 33264598 DOI: 10.1016/j.cmet.2020.11.007  0.52
2020 Carrie C, Kieffer V, Figarella-Branger D, Masliah-Planchon J, Bolle S, Bernier V, Laprie A, Supiot S, Leseur J, Habrand JL, Alapetite C, Kerr C, Dufour C, Claude L, Chapet S, et al. Exclusive Hyper-fractionated Radiotherapy and reduced boost volume for standard-risk medulloblastoma: pooled analysis of the two French multicentric studies MSFOP98 and MSFOP 2007 and correlation with molecular subgroups. International Journal of Radiation Oncology, Biology, Physics. PMID 32768563 DOI: 10.1016/J.Ijrobp.2020.07.2324  0.716
2020 Graillon T, Roche C, Basset N, Mougel G, Meyer M, Farah K, Boissonneau S, Fuentes S, Tabouret E, Campello C, Appay R, Figarella-Branger D, Chinot O, Dufour H, Romanet P, et al. Brief CommunicationCirculating tumor DNA is present in the most aggressive meningiomas. Neuro-Oncology Advances. 2: vdaa068. PMID 32642718 DOI: 10.1093/noajnl/vdaa068  0.549
2020 Appay R, Pages M, Colin C, Jones DTW, Varlet P, Figarella-Branger D. Diffuse leptomeningeal glioneuronal tumor: a double misnomer? A report of two cases. Acta Neuropathologica Communications. 8: 95. PMID 32605662 DOI: 10.1186/S40478-020-00978-7  0.672
2020 Louis DN, Wesseling P, Aldape K, Brat DJ, Capper D, Cree IA, Eberhart C, Figarella-Branger D, Fouladi M, Fuller GN, Giannini C, Haberler C, Hawkins C, Komori T, Kros JM, et al. cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading. Brain Pathology (Zurich, Switzerland). PMID 32307792 DOI: 10.1111/Bpa.12832  0.359
2020 Bergès R, Tchoghandjian A, Sergé A, Honoré S, Figarella-Branger D, Bachmann F, Lane HA, Braguer D. EB1-dependent long survival of glioblastoma-grafted mice with the oral tubulin-binder BAL101553 is associated with inhibition of tumor angiogenesis. Oncotarget. 11: 759-774. PMID 32165998 DOI: 10.18632/Oncotarget.27374  0.73
2020 Graillon T, Sanson M, Campello C, Idbaih A, Peyre M, Peyrière H, Basset N, Autran D, Roche C, Kalamarides M, Roche PH, Fuentes S, Tabouret E, Barrie M, Cohen A, ... ... Figarella-Branger D, et al. Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31969329 DOI: 10.1158/1078-0432.Ccr-19-2109  0.575
2019 Appay R, Dehais C, Maurage CA, Alentorn A, Carpentier C, Colin C, Ducray F, Escande F, Idbaih A, Kamoun A, Marie Y, Mokhtari K, Tabouret E, Trabelsi N, Uro-Coste E, ... ... Figarella-Branger D, et al. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas. Neuro-Oncology. PMID 31832685 DOI: 10.1093/Neuonc/Noz124  0.749
2019 Lambo S, Gröbner SN, Rausch T, Waszak SM, Schmidt C, Gorthi A, Romero JC, Mauermann M, Brabetz S, Krausert S, Buchhalter I, Koster J, Zwijnenburg DA, Sill M, Hübner JM, ... ... Figarella-Branger D, et al. The molecular landscape of ETMR at diagnosis and relapse. Nature. PMID 31802000 DOI: 10.1038/S41586-019-1815-X  0.313
2019 Grandin N, Pereira B, Cohen C, Billard P, Dehais C, Carpentier C, Idbaih A, Bielle F, Ducray F, Figarella-Branger D, Delattre JY, Sanson M, Lomonte P, Poncet D, Verrelle P, et al. The level of activity of the alternative lengthening of telomeres correlates with patient age in IDH-mutant ATRX-loss-of-expression anaplastic astrocytomas. Acta Neuropathologica Communications. 7: 175. PMID 31706351 DOI: 10.1186/S40478-019-0833-0  0.361
2019 Gareton A, Tauziède-Espariat A, Dangouloff-Ros V, Roux A, Saffroy R, Castel D, Kergrohen T, Fina F, Figarella-Branger D, Pagès M, Bourdeaut F, Doz F, Puget S, Dufour C, Lechapt E, et al. The histomolecular criteria established for adult anaplastic pilocytic astrocytoma are not applicable to the pediatric population. Acta Neuropathologica. PMID 31677015 DOI: 10.1007/S00401-019-02088-8  0.379
2019 Pouget C, Hergalant S, Lardenois E, Lacomme S, Houlgatte R, Carpentier C, Dehais C, Rech F, Taillandier L, Sanson M, Appay R, Colin C, Figarella-Branger D, Battaglia-Hsu SF, Gauchotte G, et al. Ki-67 and MCM6 labelling indices are correlated with overall survival in anaplastic oligodendroglioma, IDH1-mutant and 1p/19q-codeleted: a multicenter study from the French POLA network. Brain Pathology (Zurich, Switzerland). PMID 31561286 DOI: 10.1111/Bpa.12788  0.633
2019 Baeza-Kallee N, Bergès R, Soubéran A, Colin C, Denicolaï E, Appay R, Tchoghandjian A, Figarella-Branger D. Glycolipids Recognized by A2B5 Antibody Promote Proliferation, Migration, and Clonogenicity in Glioblastoma Cells. Cancers. 11. PMID 31466399 DOI: 10.3390/Cancers11091267  0.795
2019 Varlet P, Le Teuff G, Le Deley MC, Giangaspero F, Haberler C, Jacques TS, Figarella-Branger D, Pietsch T, Andreiuolo F, Deroulers C, Jaspan T, Jones C, Grill J. WHO grade has no prognostic value in the pediatric high-grade glioma included in the HERBY trial. Neuro-Oncology. PMID 31419298 DOI: 10.1093/Neuonc/Noz142  0.303
2019 Sievers P, Appay R, Schrimpf D, Stichel D, Reuss DE, Wefers AK, Reinhardt A, Coras R, Ruf VC, Schmid S, de Stricker K, Boldt HB, Kristensen BW, Petersen JK, Ulhøi BP, ... ... Figarella-Branger D, et al. Rosette-forming glioneuronal tumors share a distinct DNA methylation profile and mutations in FGFR1, with recurrent co-mutation of PIK3CA and NF1. Acta Neuropathologica. PMID 31250151 DOI: 10.1007/S00401-019-02038-4  0.393
2019 Dardaud LM, Bris C, Desquiret-Dumas V, Boisselier B, Tabouret E, Mokhtari K, Figarella-Branger D, Rousseau A, Procaccio V. High mitochondrial DNA copy number is associated with longer survival in young patients with glioblastoma. Neuro-Oncology. PMID 31095694 DOI: 10.1093/Neuonc/Noz072  0.589
2019 Louis DN, Ellison DW, Brat DJ, Aldape K, Capper D, Hawkins C, Paulus W, Perry A, Reifenberger G, Figarella-Branger D, von Deimling A, Wesseling P. cIMPACT-NOW: A practical summary of diagnostic points from Round 1 updates. Brain Pathology (Zurich, Switzerland). PMID 31038238 DOI: 10.1111/Bpa.12732  0.348
2019 Clavreul A, Soulard G, Lemée JM, Rigot M, Fabbro-Peray P, Bauchet L, Figarella-Branger D, Menei P. The French glioblastoma biobank (FGB): a national clinicobiological database. Journal of Translational Medicine. 17: 133. PMID 31014363 DOI: 10.1186/S12967-019-1859-6  0.326
2019 Soubéran A, Cappaï J, Chocry M, Nuccio C, Raujol J, Colin C, Lafitte D, Kovacic H, Quillien V, Baeza-Kallee N, Rougon G, Figarella-Branger D, Tchoghandjian A. Inhibitor of Apoptosis Proteins Determine Glioblastoma Stem-Like Cells Fate in an Oxygen-Dependent Manner. Stem Cells (Dayton, Ohio). PMID 30920104 DOI: 10.1002/Stem.2997  0.781
2019 Compes P, Tabouret E, Etcheverry A, Colin C, Appay R, Cordier N, Mosser J, Chinot O, Delingette H, Girard N, Dufour H, Metellus P, Figarella-Branger D. Correction to: Neuro-radiological characteristics of adult diffuse grade II and III insular gliomas classified according to WHO 2016. Journal of Neuro-Oncology. PMID 30859482 DOI: 10.1007/S11060-019-03141-Y  0.704
2019 Vogels R, Macagno N, Griewank K, Groenen P, Verdijk M, Fonville J, Kusters B, Figarella-Branger D, Wesseling P, Bouvier C, Flucke U. Prognostic significance of NAB2-STAT6 fusion variants and TERT promotor mutations in solitary fibrous tumors/hemangiopericytomas of the CNS: not (yet) clear. Acta Neuropathologica. PMID 30761420 DOI: 10.1007/S00401-019-01968-3  0.612
2019 Autran D, Barrie M, Matta M, Monserrat C, Campello C, Petrirena G, Boucard C, Padovani L, Loundou A, Appay R, Graillon T, Dufour H, Figarella-Branger D, Chinot O, Tabouret E. Leptomeningeal Gliomatosis: A Single Institution Study of 31 Patients. Anticancer Research. 39: 1035-1041. PMID 30711992 DOI: 10.21873/Anticanres.13210  0.695
2019 Chanez B, Appay R, Guille A, Lagarde A, Adelaide J, Denicolai E, Campello C, Tchoghandjian A, Petrirena G, Colin C, Barrie M, Baeza-Kallee N, Boucard C, Jiguet-Jiglaire C, Graillon T, ... ... Figarella-Branger D, et al. Genomic analysis of paired IDHwt glioblastoma (GB) to reveal recurrent alterations of MPDZ at relapse after radiotherapy and temozolomide (RTCT). Journal of Clinical Oncology. 37: e13535-e13535. DOI: 10.1200/Jco.2019.37.15_Suppl.E13535  0.822
2019 Garnier L, Dehais C, Curtit E, Tabouret E, Ramirez C, Vauleon E, Bourg V, Boone M, Figarella-Branger D, Ducray F. P14.76 Characteristics of anaplastic oligodendrogliomas short-term survivors: a POLA network study Neuro-Oncology. 21: iii85-iii85. DOI: 10.1093/Neuonc/Noz126.311  0.604
2019 Chanez B, Appay R, Guille A, Lagarde A, Bequet C, Jiguet-Jiglaire C, Graillon T, Dufour H, Figarella-Branger D, Chinot O, Tabouret E. P13.09 Genomic analysis of paired IDHwt glioblastoma (GB) reveals recurrent alterations of MPDZ at relapse after radiotherapy and temozolomide (RTCT) Neuro-Oncology. 21: iii64-iii64. DOI: 10.1093/Neuonc/Noz126.230  0.662
2019 Berges R, Tchoghandjian A, Serge A, Honore S, Figarella-Branger D, Bachmann F, Lane H, Braguer D. P11.31 EB1-dependent survival of glioblastoma tumor-bearing mice after treatment with the novel checkpoint activator BAL101553 is associated with inhibition of cancer stem-like cell-mediated tumor angiogenesis and astrocytic differentiation Neuro-Oncology. 21. DOI: 10.1093/Neuonc/Noz126.177  0.727
2019 Tabouret E, Tsvetkov P, Eyraud R, Peel T, Malesinski S, Figarella-Branger D, Chinot O, Devred F. OS1.7 Plasmatic differential scanning fluorimetry profiles discriminate glioma patients from healthy controls Neuro-Oncology. 21: iii7-iii7. DOI: 10.1093/Neuonc/Noz126.020  0.6
2019 Pagès M, Jones DTW, Boddaert N, Tauziède-Espariat A, Debily M, Blauwblomme T, Figarella-Branger D, Beroukhim R, Varlet P. Lgg-04. Clinico-Histo-Molecular Landscape Of Eighty-Two Pediatric And Young Adult Dysembryoplastic Neuroepithelial Tumors Neuro-Oncology. 21. DOI: 10.1093/Neuonc/Noz036.147  0.323
2019 Montégut C, Guillamo J, Ducray F, Dehais C, Chinot O, Cohen-Jonathan Moyal E, Le Rhun E, Loiseau H, Appay R, Figarella-Branger D, Delattre J, Tabouret E. Characteristics and patterns of care of high-grade IDH-mutant gliomas in elderly patients: A French POLA network study Annals of Oncology. 30: v147. DOI: 10.1093/Annonc/Mdz243.010  0.601
2019 Carrie C, Kieffer V, Figarella-Branger D, Masliah-Planchon J, Bolle S, Leseur J, Supiot S, Laprie A, Bernier V, Dufour C, Huchet A, Coche-Dequeant B, Truc G, Vigneron C, Alapetite C, et al. Medulloblastoma Molecular Subgroup and Hyperfractionated Radiation Therapy Alone for Standard Risk Medulloblastoma : Results of the Pool Data of MSFOP 1998 and 2007 Studies International Journal of Radiation Oncology Biology Physics. 105. DOI: 10.1016/J.Ijrobp.2019.06.600  0.692
2018 Fabbro-Peray P, Zouaoui S, Darlix A, Fabbro M, Pallud J, Rigau V, Mathieu-Daude H, Bessaoud F, Bauchet F, Riondel A, Sorbets E, Charissoux M, Amelot A, Mandonnet E, Figarella-Branger D, et al. Association of patterns of care, prognostic factors, and use of radiotherapy-temozolomide therapy with survival in patients with newly diagnosed glioblastoma: a French national population-based study. Journal of Neuro-Oncology. PMID 30523606 DOI: 10.1007/S11060-018-03065-Z  0.343
2018 Uro-Coste E, Masliah-Planchon J, Siegfried A, Blanluet M, Lambo S, Kool M, Roujeau T, Boetto S, Palenzuela G, Bertozzi AI, Gambart M, Coupier I, Oliver-Petit I, Golmard L, Julia S, ... ... Figarella-Branger D, et al. ETMR-like infantile cerebellar embryonal tumors in the extended morphologic spectrum of DICER1-related tumors. Acta Neuropathologica. PMID 30446821 DOI: 10.1007/S00401-018-1935-7  0.348
2018 Goschzik T, Schwalbe EC, Hicks D, Smith A, Zur Muehlen A, Figarella-Branger D, Doz F, Rutkowski S, Lannering B, Pietsch T, Clifford SC. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial. The Lancet. Oncology. PMID 30392813 DOI: 10.1016/S1470-2045(18)30532-1  0.305
2018 Muracciole X, El-Amine W, Tabouret E, Boucekine M, Barlier A, Petrirena G, Harivony T, Solignac L, Chinot OL, Macagno N, Figarella-Branger D, Padovani L. Negative Survival Impact of High Radiation Doses to Neural Stem Cells Niches in an IDH-Wild-Type Glioblastoma Population. Frontiers in Oncology. 8: 426. PMID 30338243 DOI: 10.3389/Fonc.2018.00426  0.584
2018 Berges R, Denicolai E, Tchoghandjian A, Baeza-Kallee N, Honore S, Figarella-Branger D, Braguer D. Proscillaridin A exerts anti-tumor effects through GSK3β activation and alteration of microtubule dynamics in glioblastoma. Cell Death & Disease. 9: 984. PMID 30250248 DOI: 10.1038/S41419-018-1018-7  0.802
2018 Appay R, Tabouret E, Touat M, Carpentier C, Colin C, Ducray F, Idbaih A, Mokhtari K, Uro-Coste E, Dehais C, Figarella-Branger D. Somatostatin receptor 2A protein expression characterizes anaplastic oligodendrogliomas with favorable outcome. Acta Neuropathologica Communications. 6: 89. PMID 30193580 DOI: 10.1186/S40478-018-0594-1  0.767
2018 Rosenberg S, Simeonova I, Bielle F, Verreault M, Bance B, Le Roux I, Daniau M, Nadaradjane A, Gleize V, Paris S, Marie Y, Giry M, Polivka M, Figarella-Branger D, Aubriot-Lorton MH, et al. A recurrent point mutation in PRKCA is a hallmark of chordoid gliomas. Nature Communications. 9: 2371. PMID 29915258 DOI: 10.1038/S41467-018-04622-W  0.342
2018 Appay R, Fina F, Macagno N, Padovani L, Colin C, Barets D, Ordioni J, Scavarda D, Giangaspero F, Badiali M, Korshunov A, M Pfister S, T W Jones D, Figarella-Branger D. Duplications of KIAA1549 and BRAF screening by Droplet Digital PCR from formalin-fixed paraffin-embedded DNA is an accurate alternative for KIAA1549-BRAF fusion detection in pilocytic astrocytomas. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. PMID 29802359 DOI: 10.1038/S41379-018-0050-6  0.75
2018 Mackay A, Burford A, Molinari V, Jones DTW, Izquierdo E, Brouwer-Visser J, Giangaspero F, Haberler C, Pietsch T, Jacques TS, Figarella-Branger D, Rodriguez D, Morgan PS, Raman P, Waanders AJ, et al. Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial. Cancer Cell. 33: 829-842.e5. PMID 29763623 DOI: 10.1016/J.Ccell.2018.04.004  0.356
2018 Macagno N, Vogels R, Appay R, Colin C, Mokhtari K, Küsters B, Wesseling P, Figarella-Branger D, Flucke U, Bouvier C. Grading of Meningeal Solitary Fibrous Tumors/Hemangiopericytomas: Analysis of the Prognostic Value of the Marseille Grading System in a Cohort of 132 Patients. Brain Pathology (Zurich, Switzerland). PMID 29600523 DOI: 10.1111/Bpa.12613  0.716
2018 Appay R, Tabouret E, Macagno N, Touat M, Carpentier C, Colin C, Ducray F, Idbaih A, Mokhtari K, Uro-Coste E, Dehais C, Figarella-Branger D. IDH2 mutations are commonly associated with 1p/19q codeletion in diffuse adult gliomas. Neuro-Oncology. PMID 29522183 DOI: 10.1093/Neuonc/Noy014  0.753
2018 Tsvetkov PO, Tabouret E, Roman AY, Romain S, Bequet C, Ishimbaeva O, Honoré S, Figarella-Branger D, Chinot O, Devred F. Differential scanning calorimetry of plasma in glioblastoma: toward a new prognostic / monitoring tool. Oncotarget. 9: 9391-9399. PMID 29507697 DOI: 10.18632/Oncotarget.24317  0.606
2018 Tabouret E, Compes P, Etcheverry A, Colin C, Appay R, Cordier N, Chinot OL, Delinguette H, Girard N, Dufour H, Metellus P, Figarella-Branger D. Molecular and neuro-radiological characteristics of diffuse grade II and III gliomas involving the insula. Journal of Clinical Oncology. 36: e14050-e14050. DOI: 10.1200/Jco.2018.36.15_Suppl.E14050  0.732
2018 Goschzik T, Schwalbe EC, Hicks D, Figarella-Branger D, Doz F, Rutkowski S, Gustafsson G, Lannering B, Pietsch T, Clifford SC. Abstract LB-324: A whole chromosome aberration phenotype in non-WNT/non-SHH tumors predicts outcome within standard-risk medulloblastomas from the HIT-SIOP-PNET4 clinical trial Tumor Biology. DOI: 10.1158/1538-7445.Am2018-Lb-324  0.302
2018 Alentorn A, Labreche K, Dehais C, Carpentier C, Ducray F, Mokhtari K, Figarella-Branger D, Sanson M, Delattre J, Idbaih A. P01.148 Intra-tumor heterogeneity analysis of low-grade gliomas. A POLA Network study Neuro-Oncology. 20. DOI: 10.1093/Neuonc/Noy139.190  0.359
2018 Goschzik T, Schwalbe EC, Hicks D, Figarella-Branger D, Doz F, Rutkowski S, Gustafsson G, Lannering B, Pietsch T, Clifford SC. Mbcl-31. A Whole Chromosome Aberration Phenotype In Non-Wnt/Non-Shh Tumors Predicts Outcome Within Standard-Risk Medulloblastomas From The Hit-Siop-Pnet4 Clinical Trial Neuro-Oncology. 20. DOI: 10.1093/Neuonc/Noy059.427  0.302
2018 Pietsch T, Figarella-Branger D, Giangaspero F, Gessi M, Hawkins C, Jacques T, Korshunov A, Eberhart C, Burger P, Hoff Kv, Kool M, Haberler C. Embr-12. Improved Diagnostic Algorithm For Differential Diagnostics Of Cns Embryonal Tumors (Former Cns-Pnet) By Neuropathological Re-Evaluation Of 256 Cases And Crossvalidation By Methylation Classification Neuro-Oncology. 20. DOI: 10.1093/Neuonc/Noy059.196  0.322
2018 Fina F, Henaff D, Bresson A, Juline V, Romain A, Carole C, Figarella-Branger D. Multiplex digital PCR for the diagnostic of pilocytic astrocytoma and glioneuronal tumors. Annals of Oncology. 29. DOI: 10.1093/Annonc/Mdy273.365  0.342
2017 Peyre M, Gauchotte G, Giry M, Froehlich S, Pallud J, Graillon T, Bielle F, Cazals-Hatem D, Varlet P, Figarella-Branger D, Loiseau H, Kalamarides M. De novo and secondary anaplastic meningiomas: a study of clinical and histomolecular prognostic factors. Neuro-Oncology. PMID 29216385 DOI: 10.1093/Neuonc/Nox231  0.32
2017 Berland M, Padovani L, Rome A, Pech-Gourg G, Figarella-Branger D, André N. Sustained Complete Response to Metronomic Chemotherapy in a Child with Refractory Atypical Teratoid Rhabdoid Tumor: A Case Report. Frontiers in Pharmacology. 8: 792. PMID 29163174 DOI: 10.3389/Fphar.2017.00792  0.623
2017 Bielle F, Di Stefano AL, Meyronnet D, Picca A, Villa C, Bernier M, Schmitt Y, Giry M, Rousseau A, Figarella-Branger D, Maurage CA, Uro-Coste E, Lasorella A, Iavarone A, Sanson M, et al. Diffuse gliomas with FGFR3-TACC3 fusion have characteristic histopathological and molecular features. Brain Pathology (Zurich, Switzerland). PMID 28976058 DOI: 10.1111/Bpa.12563  0.368
2017 Debruyne DN, Turchi L, Burel-Vandenbos F, Fareh M, Almairac F, Virolle V, Figarella-Branger D, Baeza-Kallee N, Lagadec P, Kubiniek V, Paquis P, Fontaine D, Junier MP, Chneiweiss H, Virolle T. DOCK4 promotes loss of proliferation in glioblastoma progenitor cells through nuclear beta-catenin accumulation and subsequent miR-302-367 cluster expression. Oncogene. PMID 28925399 DOI: 10.1038/Onc.2017.323  0.303
2017 Graillon T, Romano D, Defilles C, Lisbonis C, Saveanu A, Figarella-Branger D, Roche PH, Fuentes S, Chinot O, Dufour H, Barlier A. Pasireotide is more effective than octreotide, alone or combined with everolimus on human meningioma in vitro. Oncotarget. 8: 55361-55373. PMID 28903425 DOI: 10.18632/Oncotarget.19517  0.33
2017 Appay R, Macagno N, Padovani L, Korshunov A, Kool M, André N, Scavarda D, Pietsch T, Figarella-Branger D. HGNET-BCOR Tumors of the Cerebellum: Clinicopathologic and Molecular Characterization of 3 Cases. The American Journal of Surgical Pathology. PMID 28704208 DOI: 10.1097/Pas.0000000000000866  0.648
2017 Tauziede-Espariat A, Parfait B, Besnard A, Lacombe J, Pallud J, Tazi S, Puget S, Lot G, Terris B, Cohen J, Vidaud M, Figarella-Branger D, Monnien F, Polivka M, Adle-Biassette H, et al. Loss of smarce1 expression is a specific diagnostic marker of clear cell meningioma: A comprehensive immunophenotypical and molecular analysis. Brain Pathology (Zurich, Switzerland). PMID 28474749 DOI: 10.1111/Bpa.12524  0.412
2017 Terrier LM, Bauchet L, Rigau V, Amelot A, Zouaoui S, Filipiak I, Caille A, Almairac F, Aubriot-Lorton MH, Bergemer-Fouquet AM, Bord E, Cornu P, Czorny A, Dam Hieu P, Debono B, ... ... Figarella-Branger D, et al. Natural course and prognosis of anaplastic gangliogliomas: a multicenter retrospective study of 43 cases from the French Brain Tumor Database. Neuro-Oncology. 19: 678-688. PMID 28453747 DOI: 10.1093/Neuonc/Now186  0.373
2017 Macagno N, Fuentes S, de Pinieux G, Maues de Paula A, Salas S, Mattéi JC, Dupuis C, Appay R, Aurias A, Dufour H, Figarella-Branger D, Bouvier C. Paravertebral Well-Differentiated Liposarcoma with Low-Grade Osteosarcomatous Component: Case Report with 11-Year Follow-Up, Radiological, Pathological, and Genetic Data, and Literature Review. Case Reports in Pathology. 2017: 2346316. PMID 28377828 DOI: 10.1155/2017/2346316  0.623
2017 Verger A, Metellus P, Sala Q, Colin C, Bialecki E, Taieb D, Chinot O, Figarella-Branger D, Guedj E. IDH mutation is paradoxically associated with higher (18)F-FDOPA PET uptake in diffuse grade II and grade III gliomas. European Journal of Nuclear Medicine and Molecular Imaging. PMID 28293705 DOI: 10.1007/S00259-017-3668-6  0.629
2017 Graillon T, Sanson M, Peyre M, Peyrière H, Autran D, Kalamarides M, Roche P, Fuentes S, Tabouret E, Barrie M, Campello C, Idbaih A, Boucekine M, Figarella-Branger D, Barlier A, et al. MNGI-13. FINAL ANALYSIS OF PHASE II COMBINING EVEROLIMUS AND OCTREOTIDE FOR PATIENTS WITH REFRACTORY AND DOCUMENTED PROGRESSIVE MENINGIOMA (CEVOREM) Neuro-Oncology. 19: vi134-vi135. DOI: 10.1093/Neuonc/Nox168.551  0.562
2017 Pagès M, Tauziède-Espariat A, Beccaria K, Boddaert N, Saffroy R, Besnard A, Castel D, Fina F, Barets D, Barret E, Lacroix L, Bielle F, Andreiuolo F, Figarella-Branger D, Puget S, et al. Gene-06. Co-Occurrence Of Double Mutation H3F3A/Braf In Pediatric Gangliogliomas. Neuro-Oncology. 19. DOI: 10.1093/Neuonc/Nox083.077  0.361
2016 Louis DN, Aldape K, Brat DJ, Capper D, Ellison DW, Hawkins C, Paulus W, Perry A, Reifenberger G, Figarella-Branger D, Wesseling P, Batchelor TT, Gregory Cairncross J, Pfister SM, Rutkowski S, et al. cIMPACT-NOW (the consortium to inform molecular and practical approaches to CNS tumor taxonomy): a new initiative in advancing nervous system tumor classification. Brain Pathology (Zurich, Switzerland). PMID 27997995 DOI: 10.1111/Bpa.12457  0.346
2016 Pagès M, Beccaria K, Boddaert N, Saffroy R, Besnard A, Castel D, Fina F, Barets D, Barret E, Lacroix L, Bielle F, Andreiuolo F, Tauziède-Espariat A, Figarella-Branger D, Puget S, et al. Co-occurrence of Histone H3 K27M and BRAF V600E mutations in paediatric midline grade I ganglioglioma. Brain Pathology (Zurich, Switzerland). PMID 27984673 DOI: 10.1111/Bpa.12473  0.307
2016 Graillon T, Romano D, Defilles C, Saveanu A, Mohamed A, Figarella-Branger D, Roche PH, Fuentes S, Chinot O, Dufour H, Barlier A. Octreotide therapy in meningiomas: in vitro study, clinical correlation, and literature review. Journal of Neurosurgery. 1-10. PMID 27982767 DOI: 10.3171/2016.8.Jns16995  0.403
2016 Darlix A, Zouaoui S, Rigau V, Bessaoud F, Figarella-Branger D, Mathieu-Daudé H, Trétarre B, Bauchet F, Duffau H, Taillandier L, Bauchet L. Erratum to: Epidemiology for primary brain tumors: a nationwide population-based study. Journal of Neuro-Oncology. PMID 27957669 DOI: 10.1007/S11060-016-2340-5  0.322
2016 Louis DN, Aldape K, Brat DJ, Capper D, Ellison DW, Hawkins C, Paulus W, Perry A, Reifenberger G, Figarella-Branger D, Wesseling P, Batchelor TT, Cairncross JG, Pfister SM, Rutkowski S, et al. Announcing cIMPACT-NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy. Acta Neuropathologica. PMID 27909809 DOI: 10.1007/S00401-016-1646-X  0.355
2016 Darlix A, Zouaoui S, Rigau V, Bessaoud F, Figarella-Branger D, Mathieu-Daudé H, Trétarre B, Bauchet F, Duffau H, Taillandier L, Bauchet L. Epidemiology for primary brain tumors: a nationwide population-based study. Journal of Neuro-Oncology. PMID 27853959 DOI: 10.1007/S11060-016-2318-3  0.332
2016 Fina F, Barets D, Colin C, Bouvier C, Padovani L, Nanni-Metellus I, Ouafik L, Scavarda D, Korshunov A, Jones DT, Figarella-Branger D. Droplet digital PCR is a powerful technique to demonstrate frequent FGFR1 duplication in dysembryoplastic neuroepithelial tumors. Oncotarget. PMID 27791984 DOI: 10.18632/Oncotarget.12881  0.796
2016 Lamballe F, Toscano S, Conti F, Arechederra M, Baeza N, Figarella-Branger D, Helmbacher F, Maina F. Coordination of signalling networks and tumorigenic properties by ABL in glioblastoma cells. Oncotarget. PMID 27732969 DOI: 10.18632/Oncotarget.12546  0.319
2016 Tabouret E, Nguyen AT, Dehais C, Carpentier C, Ducray F, Idbaih A, Mokhtari K, Jouvet A, Uro-Coste E, Colin C, Chinot O, Loiseau H, Moyal E, Maurage CA, Polivka M, ... ... Figarella-Branger D, et al. Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort. Acta Neuropathologica. PMID 27573687 DOI: 10.1007/S00401-016-1611-8  0.756
2016 Tabouret E, Denicolai E, Delfino C, Graillon T, Boucard C, Nanni I, Padovani L, Figarella-Branger D, Chinot O. Changes in PlGF and MET-HGF expressions in paired initial and recurrent glioblastoma. Journal of Neuro-Oncology. 130: 431-437. PMID 27566180 DOI: 10.1007/S11060-016-2251-5  0.803
2016 Berges R, Tchoghandjian A, Honore S, Esteve MA, Figarella-Branger D, Bachmann F, Lane HA, Braguer D. The novel tubulin-binding, checkpoint activator BAL101553 inhibits EB1-dependent migration and invasion and promotes differentiation of glioblastoma stem-like cells. Molecular Cancer Therapeutics. PMID 27540016 DOI: 10.1158/1535-7163.Mct-16-0252  0.735
2016 Tchoghandjian A, Soubéran A, Tabouret E, Colin C, Denicolaï E, Jiguet-Jiglaire C, El-Battari A, Villard C, Baeza-Kallee N, Figarella-Branger D. Inhibitor of apoptosis protein expression in glioblastomas and their in vitro and in vivo targeting by SMAC mimetic GDC-0152. Cell Death & Disease. 7: e2325. PMID 27490930 DOI: 10.1038/Cddis.2016.214  0.802
2016 Mascelli S, Nozza P, Jones DT, Colin C, Pistorio A, Milanaccio C, Ravegnani M, Consales A, Witt O, Morana G, Cama A, Capra V, Biassoni R, Pfister SM, Figarella-Branger D, et al. TP53 codon 72 polymorphism may predict early tumour progression in paediatric pilocytic astrocytoma. Oncotarget. PMID 27374106 DOI: 10.18632/Oncotarget.10295  0.637
2016 Joubert C, Boissonneau S, Fina F, Figarella-Branger D, Ouafik L, Fuentes S, Dufour H, Gonçalves A, Charaffe-Jauffret E, Metellus P. [Immunohistochemical hormonal mismatch and human epidermal growth factor type 2 [HER2] phenotype of brain metastases in breast cancer carcinoma compared to primary tumors]. Neuro-Chirurgie. PMID 27236733 DOI: 10.1016/J.Neuchi.2016.01.007  0.329
2016 Ricard C, Tchoghandjian A, Luche H, Grenot P, Figarella-Branger D, Rougon G, Malissen M, Debarbieux F. Phenotypic dynamics of microglial and monocyte-derived cells in glioblastoma-bearing mice. Scientific Reports. 6: 26381. PMID 27193333 DOI: 10.1038/Srep26381  0.798
2016 Figarella-Branger D, Mokhtari K, Dehais C, Carpentier C, Colin C, Jouvet A, Uro-Coste E, Forest F, Maurage CA, Vignaud JM, Polivka M, Lechapt-Zalcman E, Eimer S, Viennet G, Quintin-Roué I, et al. Mitotic index, microvascular proliferation, and necrosis define 3 pathological subgroups of prognostic relevance among 1p/19q co-deleted anaplastic oligodendrogliomas. Neuro-Oncology. 18: 888-90. PMID 27175000 DOI: 10.1093/Neuonc/Now085  0.624
2016 Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathologica. 131: 803-20. PMID 27157931 DOI: 10.1007/S00401-016-1545-1  0.405
2016 Kamoun A, Idbaih A, Dehais C, Elarouci N, Carpentier C, Letouzé E, Colin C, Mokhtari K, Jouvet A, Uro-Coste E, Martin-Duverneuil N, Sanson M, Delattre JY, Figarella-Branger D, de Reyniès A, et al. Integrated multi-omics analysis of oligodendroglial tumours identifies three subgroups of 1p/19q co-deleted gliomas. Nature Communications. 7: 11263. PMID 27090007 DOI: 10.1038/Ncomms11263  0.652
2016 Heng MA, Padovani L, Dory-Lautrec P, Gentet JC, Verschuur A, Pasquier E, Figarella-Branger D, Scavarda D, André N. Can metronomic maintenance with weekly vinblastine prevent early relapse/progression after bevacizumab-irinotecan in children with low-grade glioma? Cancer Medicine. 5: 1542-5. PMID 27037940 DOI: 10.1002/Cam4.699  0.592
2016 Sakakini N, Turchi L, Bergon A, Holota H, Rekima S, Lopez F, Paquis P, Almairac F, Fontaine D, Baeza-Kallee N, Van Obberghen-Schilling E, Junier MP, Chneiweiss H, Figarella-Branger D, Burel-Vandenbos F, et al. A Positive Feed-forward Loop Associating EGR1 and PDGFA Promotes Proliferation and Self-renewal in Glioblastoma Stem Cells. The Journal of Biological Chemistry. 291: 10684-99. PMID 27002148 DOI: 10.1074/Jbc.M116.720698  0.428
2016 Tchoghandjian A, Koh MY, Taieb D, Ganaha S, Powis G, Bialecki E, Graziani N, Figarella-Branger D, Metellus P. Hypoxia-associated factor expression in low-grade and anaplastic gliomas: a marker of poor outcome. Oncotarget. PMID 26989023 DOI: 10.18632/Oncotarget.8046  0.741
2016 Figarella-Branger D, Lechapt-Zalcman E, Tabouret E, Jünger S, de Paula AM, Bouvier C, Colin C, Jouvet A, Forest F, Andreiuolo F, Quintin-Roue I, Machet MC, Heitzmann A, Milin S, Sevestre H, et al. Supratentorial clear cell ependymomas with branching capillaries demonstrate characteristic clinicopathological features and pathological activation of nuclear factor-kappaB signaling. Neuro-Oncology. PMID 26984744 DOI: 10.1093/Neuonc/Now025  0.787
2016 Sturm D, Orr BA, Toprak UH, Hovestadt V, Jones DT, Capper D, Sill M, Buchhalter I, Northcott PA, Leis I, Ryzhova M, Koelsche C, Pfaff E, Allen SJ, Balasubramanian G, ... ... Figarella-Branger D, et al. New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. Cell. 164: 1060-1072. PMID 26919435 DOI: 10.1016/J.Cell.2016.01.015  0.399
2016 Koob M, Girard N, Ghattas B, Fellah S, Confort-Gouny S, Figarella-Branger D, Scavarda D. The diagnostic accuracy of multiparametric MRI to determine pediatric brain tumor grades and types. Journal of Neuro-Oncology. 127: 345-53. PMID 26732081 DOI: 10.1007/S11060-015-2042-4  0.373
2016 Denicolaï E, Tabouret E, Colin C, Metellus P, Nanni I, Boucard C, Tchoghandjian A, Meyronet D, Baeza-Kallee N, Chinot O, Figarella-Branger D. Molecular heterogeneity of glioblastomas: does location matter? Oncotarget. 7: 902-13. PMID 26637806 DOI: 10.18632/Oncotarget.6433  0.803
2016 Masliah-Planchon J, Machet MC, Fréneaux P, Jourdain A, Mortemousque I, Raïs KA, Ballet S, Jouvet A, Figarella-Branger D, Delattre O, Bourdeaut F. SMARCA4-Mutated Atypical Teratoid/Rhabdoid Tumor with Retained BRG1 Expression. Pediatric Blood & Cancer. 63: 568-9. PMID 26469284 DOI: 10.1002/Pbc.25772  0.377
2016 Macagno N, Figarella-Branger D, Mokthari K, Metellus P, Jouvet A, Vasiljevic A, Loundou A, Bouvier C. Differential Diagnosis of Meningeal SFT-HPC and Meningioma: Which Immunohistochemical Markers Should Be Used? The American Journal of Surgical Pathology. 40: 270-8. PMID 26448189 DOI: 10.1097/Pas.0000000000000526  0.573
2016 Tabouret E, Nguyen AT, Dehais C, Carpentier C, Lebouil L, Ducray F, Idbaih A, Moktari K, Jouvet A, uro-Coste E, Delattre J, Figarella-Branger D. Validation of the new glioma WHO classification in the french POLA network: Analysis of 1041 cases. Journal of Clinical Oncology. 34: 2015-2015. DOI: 10.1200/Jco.2016.34.15_Suppl.2015  0.625
2016 Denicolai E, Figarella-Branger D, Chinot O, Tabouret E. ANGI-06. MMP9 AND MMP2 EXHIBIT DISTINCT INTRATUMORAL EXPRESSION PATTERN IN PAIRED INITIAL AND RECURRENT GLIOBLASTOMA (GB) Neuro-Oncology. 18: vi16-vi16. DOI: 10.1093/Neuonc/Now212.061  0.557
2016 Tsvetkov PO, Tabouret E, Roman A, Ishimbaeva O, Kubatiev AA, Romain S, Figarella-Branger D, Chinot O, Devred F. ACTR-34. ANALYSIS OF PLASMATIC SIGNATURE OF GLIOBLASTOMA PATIENTS OBTAINED BY DIFFERENTIAL SCANNING CALORIMETRY REVEALS THREE PROGNOSTIC CLUSTERS Neuro-Oncology. 18: vi9-vi9. DOI: 10.1093/Neuonc/Now212.032  0.562
2016 Graillon T, Romano D, Defilles C, Figarella-Branger D, Roche P, Dufour H, Chinot O, Barlier A. P11.11 Aggressive Meningiomas: In vitro study of the combination pasireotide-everolimus vs. octreotide everolimus. Neuro-Oncology. 18. DOI: 10.1093/Neuonc/Now188.242  0.382
2016 Alentorn A, Kamoun A, Ducray F, Dehais C, Mokhtari K, Uro-Coste E, Figarella-Branger D, Delattre J, Idbaih A, Sanson M. P06.18 DNA methylation distance score in lower-grade gliomas has prognostic value: a POLA network study. Neuro-Oncology. 18. DOI: 10.1093/Neuonc/Now188.109  0.367
2015 Taïeb D, Barlier A, Yang C, Pertuit M, Tchoghandjian A, Rochette C, Zattara-Canoni H, Figarella-Branger D, Zhuang Z, Pacak K, Metellus P. Somatic gain-of-function HIF2A mutations in sporadic central nervous system hemangioblastomas. Journal of Neuro-Oncology. PMID 26514359 DOI: 10.1007/S11060-015-1983-Y  0.698
2015 Tabouret E, Bequet C, Denicolaï E, Barrié M, Nanni I, Metellus P, Dufour H, Chinot O, Figarella-Branger D. BRAF mutation and anaplasia may be predictive factors of progression-free survival in adult pleomorphic xanthoastrocytoma. European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 41: 1685-90. PMID 26454767 DOI: 10.1016/J.Ejso.2015.09.012  0.611
2015 Alentorn A, Dehais C, Ducray F, Carpentier C, Mokhtari K, Figarella-Branger D, Chinot O, Cohen-Moyal E, Ramirez C, Loiseau H, Elouahdani-Hamdi S, Beauchesne P, Langlois O, Desenclos C, Guillamo JS, et al. Allelic loss of 9p21.3 is a prognostic factor in 1p/19q codeleted anaplastic gliomas. Neurology. 85: 1325-31. PMID 26385879 DOI: 10.1212/Wnl.0000000000002014  0.318
2015 Bruno A, Alentorn A, Daniau M, Labussière M, Rahimian A, Tabouret E, Polivka M, Jouvet A, Adam C, Figarella-Branger D, Chrétien F, Eimer S, Houillier C, Soussain C, Mokhtari K, et al. TERT promoter mutations in primary central nervous system lymphoma are associated with spatial distribution in the splenium. Acta Neuropathologica. 130: 439-40. PMID 26195323 DOI: 10.1007/S00401-015-1461-9  0.587
2015 Labreche K, Simeonova I, Kamoun A, Gleize V, Chubb D, Letouzé E, Riazalhosseini Y, Dobbins SE, Elarouci N, Ducray F, de Reyniès A, Zelenika D, Wardell CP, Frampton M, Saulnier O, ... ... Figarella-Branger D, et al. TCF12 is mutated in anaplastic oligodendroglioma. Nature Communications. 6: 7207. PMID 26068201 DOI: 10.1038/Ncomms8207  0.318
2015 Graillon T, Defilles C, Mohamed A, Lisbonis C, Germanetti AL, Chinot O, Figarella-Branger D, Roche PH, Adetchessi T, Fuentes S, Metellus P, Dufour H, Enjalbert A, Barlier A. Combined treatment by octreotide and everolimus: Octreotide enhances inhibitory effect of everolimus in aggressive meningiomas. Journal of Neuro-Oncology. 124: 33-43. PMID 26015296 DOI: 10.1007/S11060-015-1812-3  0.363
2015 Tabouret E, Tchoghandjian A, Denicolai E, Delfino C, Metellus P, Graillon T, Boucard C, Nanni I, Padovani L, Ouafik L, Figarella-Branger D, Chinot O. Recurrence of glioblastoma after radio-chemotherapy is associated with an angiogenic switch to the CXCL12-CXCR4 pathway. Oncotarget. 6: 11664-75. PMID 25860928 DOI: 10.18632/Oncotarget.3256  0.808
2015 Bielle F, Villa C, Giry M, Bergemer-Fouquet AM, Polivka M, Vasiljevic A, Aubriot-Lorton MH, Bernier M, Lechapt-Zalcman E, Viennet G, Sazdovitch V, Duyckaerts C, Sanson M, Figarella-Branger D, Mokhtari K, et al. Chordoid Gliomas of the Third Ventricle Share TTF-1 Expression With Organum Vasculosum of the Lamina Terminalis. The American Journal of Surgical Pathology. 39: 948-56. PMID 25786084 DOI: 10.1097/Pas.0000000000000421  0.359
2015 Figarella-Branger D, Mokhtari K, Colin C, Uro-Coste E, Jouvet A, Dehais C, Carpentier C, Villa C, Maurage CA, Eimer S, Polivka M, Vignaud JM, Laquerriere A, Sevestre H, Lechapt-Zalcman E, et al. Prognostic Relevance of Histomolecular Classification of Diffuse Adult High-Grade Gliomas with Necrosis. Brain Pathology (Zurich, Switzerland). 25: 418-28. PMID 25407774 DOI: 10.1111/Bpa.12227  0.684
2015 Nguyen AT, Colin C, Nanni-Metellus I, Padovani L, Maurage CA, Varlet P, Miquel C, Uro-Coste E, Godfraind C, Lechapt-Zalcman E, Labrousse F, Gauchotte G, Silva K, Jouvet A, Figarella-Branger D, et al. Evidence for BRAF V600E and H3F3A K27M double mutations in paediatric glial and glioneuronal tumours. Neuropathology and Applied Neurobiology. 41: 403-8. PMID 25389051 DOI: 10.1111/Nan.12196  0.709
2015 Bauchet L, Rigau V, Zouaoui S, Darlix A, Bessaoud F, Bauchet F, Figarella-Branger D, Fabbro-Peray P, Tretarre B, Fabbro M, Charissoux M, Kerr C, Goze C, Capelle L, Duffau H, et al. French national histological brain tumor registry. Journal of Clinical Oncology. 33. DOI: 10.1200/Jco.2015.33.15_Suppl.E13051  0.359
2015 Denicolai E, Tabouret E, Colin C, Metellus P, Nanni I, Boucard C, Tchoghandjian A, Baeza-Kallee N, Fina F, Chinot OL, Figarella-Branger D. Differential molecular expression profile according to glioblastoma (GB) location. Journal of Clinical Oncology. 33: 2030-2030. DOI: 10.1200/Jco.2015.33.15_Suppl.2030  0.789
2015 Bruno A, Daniau M, Mokhtari K, Rahimian A, Polivka M, Jouvet A, Adam C, Figarella-Branger D, Miquel C, Eimer S, Houillier C, Soussain C, Alentorn A, Hoang-Xuan K. Abstract 3896: Recurrent TERT promoter mutations in primary central nervous system lymphoma Cancer Research. 75: 3896-3896. DOI: 10.1158/1538-7445.Am2015-3896  0.326
2015 Berges R, Tchoghandjian A, Honore S, Figarella-Branger D, Bachmann F, Lane H, Braguer D. Abstract A183: The novel tubulin-binding ‘tumor checkpoint controller’ BAL101553 exerts EB1 expression-dependent antitumor effects on glioblastoma stem-like cells in vitro and in vivo Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-A183  0.722
2015 Kamoun A, Ducray F, Dehais C, Idbaih A, Elarouci N, Letouze E, Figarella-Branger D, de Reyniès A, Delattre J. GENO-19INTEGRATED GENOMIC ANALYSIS OF OLIGODENDROGLIAL TUMORS IDENTIFIES DISTINCT MOLECULAR SUBGROUPS WITHIN 1p/19q CO-DELETED OLIGODENDROGLIOMAS Neuro-Oncology. 17: v95.3-v95. DOI: 10.1093/Neuonc/Nov215.19  0.428
2015 Bruno A, Alentorn A, Daniau M, Labussière M, Rahimian A, Tabouret E, Polivka M, Jouvet A, Adam C, Figarella-Branger D, Chrétien F, Eimer S, Houillier C, Soussain C, Mokhtari K, et al. TERT promoter mutations in primary central nervous system lymphoma are associated with spatial distribution in the splenium Acta Neuropathologica. 130: 439-440. DOI: 10.1007/s00401-015-1461-9  0.519
2014 Ait-Belkacem R, Berenguer C, Villard C, Ouafik L, Figarella-Branger D, Beck A, Chinot O, Lafitte D. Monitoring therapeutic monoclonal antibodies in brain tumor. Mabs. 6: 1385-93. PMID 25484065 DOI: 10.4161/Mabs.34405  0.331
2014 Berges R, Baeza-Kallee N, Tabouret E, Chinot O, Petit M, Kruczynski A, Figarella-Branger D, Honore S, Braguer D. End-binding 1 protein overexpression correlates with glioblastoma progression and sensitizes to Vinca-alkaloids in vitro and in vivo. Oncotarget. 5: 12769-87. PMID 25473893 DOI: 10.18632/Oncotarget.2646  0.637
2014 Denicolaï E, Baeza-Kallee N, Tchoghandjian A, Carré M, Colin C, Jiglaire CJ, Mercurio S, Beclin C, Figarella-Branger D. Proscillaridin A is cytotoxic for glioblastoma cell lines and controls tumor xenograft growth in vivo. Oncotarget. 5: 10934-48. PMID 25400117 DOI: 10.18632/Oncotarget.2541  0.798
2014 Etcheverry A, Aubry M, Idbaih A, Vauleon E, Marie Y, Menei P, Boniface R, Figarella-Branger D, Karayan-Tapon L, Quillien V, Sanson M, De Tayrac M, Delattre JY, Mosser J. DGKI methylation status modulates the prognostic value of MGMT in glioblastoma patients treated with combined radio-chemotherapy with temozolomide Plos One. 9. PMID 25233099 DOI: 10.1371/Journal.Pone.0104455  0.316
2014 Laffaire J, Stefano ALD, Chinot O, Idbaih A, Gallego Perez-Larraya J, Marie Y, Vintonenko N, Boisselier B, Farina P, Delattre JY, Figarella-Branger D, Honnorat J, Sanson M, Ducray F. An ANOCEF genomic and transcriptomic microarray study of the response to irinotecan and bevacizumab in recurrent glioblastomas Biomed Research International. 2014. PMID 24804210 DOI: 10.1155/2014/282815  0.309
2014 Figarella-Branger D, Mokhtari K, Dehais C, Jouvet A, Uro-Coste E, Colin C, Carpentier C, Forest F, Maurage CA, Vignaud JM, Polivka M, Lechapt-Zalcman E, Eimer S, Viennet G, Quintin-Roué I, et al. Mitotic index, microvascular proliferation, and necrosis define 3 groups of 1p/19q codeleted anaplastic oligodendrogliomas associated with different genomic alterations. Neuro-Oncology. 16: 1244-54. PMID 24723566 DOI: 10.1093/Neuonc/Nou047  0.621
2014 Meyronet D, Silva K, Figarella-Branger D, Godfraind C, Delisle MB, Maurage CA, Miquel C, Varlet P, Gentet JC, Salamon AI, Vasiljevic A, Jouvet A. [National network of paediatric central nervous system tumours reviewing by the Groupe d'Étude de Neuropathologie Oncologique Pediatrique (GENOP)]. Annales De Pathologie. 34: 74-86. PMID 24630640 DOI: 10.1016/J.Annpat.2014.01.002  0.315
2014 Ait-Belkacem R, Berenguer C, Villard C, Ouafik L, Figarella-Branger D, Chinot O, Lafitte D. MALDI imaging and in-source decay for top-down characterization of glioblastoma. Proteomics. 14: 1290-301. PMID 24376047 DOI: 10.1002/Pmic.201300329  0.357
2014 Forest F, N'Guyen AT, Fesselet J, Metellus P, Bouvier C, De Paula AM, Roche PH, Figarella-Branger D. Meningeal Rosai-Dorfman disease mimicking meningioma Annals of Hematology. 93: 937-940. PMID 24366336 DOI: 10.1007/S00277-013-1994-8  0.53
2014 Jiguet Jiglaire C, Baeza-Kallee N, Denicolaï E, Barets D, Metellus P, Padovani L, Chinot O, Figarella-Branger D, Fernandez C. Ex vivo cultures of glioblastoma in three-dimensional hydrogel maintain the original tumor growth behavior and are suitable for preclinical drug and radiation sensitivity screening. Experimental Cell Research. 321: 99-108. PMID 24355810 DOI: 10.1016/J.Yexcr.2013.12.010  0.784
2014 Reyes-Botero G, Dehais C, Idbaih A, Martin-Duverneuil N, Lahutte M, Carpentier C, Letouzé E, Chinot O, Loiseau H, Honnorat J, Ramirez C, Moyal E, Figarella-Branger D, Ducray F. Contrast enhancement in 1p/19q-codeleted anaplastic oligodendrogliomas is associated with 9p loss, genomic instability, and angiogenic gene expression. Neuro-Oncology. 16: 662-70. PMID 24353325 DOI: 10.1093/Neuonc/Not235  0.313
2014 Tabouret E, Boudouresque F, Barrie M, Matta M, Boucard C, Loundou A, Carpentier A, Sanson M, Metellus P, Figarella-Branger D, Ouafik L, Chinot O. Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma. Neuro-Oncology. 16: 392-9. PMID 24327581 DOI: 10.1093/Neuonc/Not226  0.6
2014 Serres E, Debarbieux F, Stanchi F, Maggiorella L, Grall D, Turchi L, Burel-Vandenbos F, Figarella-Branger D, Virolle T, Rougon G, Obberghen-Schilling EV. Fibronectin expression in glioblastomas promotes cell cohesion, collective invasion of basement membrane in vitro and orthotopic tumor growth in mice Oncogene. 33: 3451-3462. PMID 23912459 DOI: 10.1038/Onc.2013.305  0.405
2014 Autran D, Tabouret E, Barrie M, Matta M, Monserrat C, Boucard C, Terciolo A, Loundou A, Metellus P, Dufour H, Figarella-Branger D, Chinot OL. Leptomeningeal gliomatosis: A single institution retrospective study of 31 patients. Journal of Clinical Oncology. 32: e13017-e13017. DOI: 10.1200/Jco.2014.32.15_Suppl.E13017  0.578
2014 De Cock L, Sala Q, Barrie M, Boucard C, Terciolo A, Graillon T, Metellus P, Autran D, Tabouret E, Padovani L, Figarella-Branger D, Dufour H, Chinot OL. Patterns of care and outcome for patients with recurrent glioblastoma (GB). Journal of Clinical Oncology. 32: e13007-e13007. DOI: 10.1200/Jco.2014.32.15_Suppl.E13007  0.7
2014 Tabouret E, Boudouresque F, Denicolai E, Barrie M, Boucard C, Metellus P, Autran D, Terciolo A, Figarella-Branger D, Ouafik L, Chinot OL. Plasma levels and tumor tissue RNA of MMP2 and MMP9 exhibit similar distribution in newly diagnosed and recurrent glioblastoma (GB). Journal of Clinical Oncology. 32: 2074-2074. DOI: 10.1200/Jco.2014.32.15_Suppl.2074  0.571
2014 Tabouret E, Tchoghandjian A, Denicolai E, Delfino C, Metellus P, Padovani L, Nanni I, Barrie M, Boucard C, Ouafik L, Figarella-Branger D, Chinot OL. Expression profile of angiogenic factors in paired initial and recurrent glioblastoma. Journal of Clinical Oncology. 32: 2060-2060. DOI: 10.1200/Jco.2014.32.15_Suppl.2060  0.791
2014 Bruno A, Boisselier B, Labreche K, Marie Y, Polivka M, Jouvet A, Adam C, Figarella-Branger D, Miquel C, Vital A, Houillier C, Soussain C, Mokhtari K, Daveau R, Hoang-Xuan K. Abstract 5192: Mutational analysis of primary central nervous system lymphoma Cancer Research. 74: 5192-5192. DOI: 10.1158/1538-7445.Am2014-5192  0.367
2014 Tchoghandjian A, Jennewein C, Eckhardt I, Momma S, Figarella-Branger D, Fulda S. Abstract 5119: Smac mimetic inhibits tumorigenicity and growth of glioblastoma by promoting differentiation of glioblastoma cancer stem-like cells Cancer Research. 74: 5119-5119. DOI: 10.1158/1538-7445.Am2014-5119  0.368
2014 Tabouret E, Tchoghandjian A, Denicolai E, Delfino C, Metellus P, Padovani L, Nanni I, Barrie M, Boucard C, Ouafik L, Figarella-Branger D, Chinot O. AI-29 * ANGIOGENIC SWITCH FROM VEGFR2/HIF1  IN NEWLY DIAGNOSED GLIOBLASTOMA (GB) TO CXCR4-SDF1 PATHWAY IN RECURRENT PAIRED TUMOR AFTER RADIOTHERAPY (RT)-TEMOZOLOMIDE (TMZ) Neuro-Oncology. 16: v7-v7. DOI: 10.1093/Neuonc/Nou238.29  0.816
2014 Chinot O, Boudouresque F, Barrie M, Matta M, Boucard C, Loundou A, Figarella-Branger D, Ouafik L, Tabouret E. ASSOCIATION OF MATRIX METALLOPROTEINASE 2 (MMP2) BASELINE PLASMA LEVEL WITH RESPONSE AND SURVIVAL AND CHANGE OVERTIME IN PATIENTS TREATED WITH BEVACIZUMAB FOR RECURRENT HIGH GRADE GLIOMA Neuro-Oncology. 16: iii48-iii48. DOI: 10.1093/Neuonc/Nou209.23  0.585
2014 De Cock L, Sala Q, Barrie M, Boucard C, Metellus P, Tabouret E, Padovani L, Figarella-Branger D, Dufour H, Chinot O. P17.20 * PATTERNS OF CARE AND OUTCOME FOR PATIENTS WITH RECURRENT GLIOBLASTOMA Neuro-Oncology. 16: ii91-ii91. DOI: 10.1093/Neuonc/Nou174.350  0.695
2014 Alentorn A, Dehais C, Carpentier C, Mokhtari K, Ducray F, Figarella-Branger D, Delattre J, Idbaih A, (POLA)" PNPecdOA. P17.01 * CHROMOSOME ARM 9P LOSS OF HETEROZYGOSITY IS A MARKER OF SHORTER SURVIVAL IN 1P/19Q CO-DELETED ANAPLASTIC OLIGODENDROGLIOMA. A POLA NETWORK STUDY Neuro-Oncology. 16: ii86-ii87. DOI: 10.1093/Neuonc/Nou174.331  0.356
2014 Autran D, Tabouret E, Barrie M, Boucard C, Terciolo A, Loundou A, Metellus P, Dufour H, Figarella-Branger D, Chinot OL. P08.07 * LEPTOMENINGEAL GLIOMATOSIS: A SINGLE INSTITUTION RETROSPECTIVE STUDY OF 31 PATIENTS Neuro-Oncology. 16: ii51-ii52. DOI: 10.1093/Neuonc/Nou174.195  0.589
2014 Tabouret E, Boudouresque F, Denicolai E, Barrie M, Boucard C, Metellus P, Autran D, Figarella-Branger D, Ouafik L, Chinot O. P04.08 * PLASMA LEVELS AND TUMOR TISSUE RNA OF MMP2 AND MMP9 EXHIBIT SIMILAR DISTRIBUTION IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA (GB) Neuro-Oncology. 16: ii38-ii38. DOI: 10.1093/Neuonc/Nou174.140  0.556
2014 Tabouret E, Tchoghandjian A, Denicolai E, Delfino C, Metellus P, Barrie M, Boucard C, Ouafik L, Figarella-Branger D, Chinot O. P04.07 * EXPRESSION PROFILE OF ANGIOGENIC FACTORS IN PAIRED INITIAL AND RECURRENT GLIOBLASTOMA Neuro-Oncology. 16: ii38-ii38. DOI: 10.1093/Neuonc/Nou174.139  0.77
2013 Mercurio S, Padovani L, Colin C, Carré M, Tchoghandjian A, Scavarda D, Lambert S, Baeza-Kallee N, Fernandez C, Chappé C, André N, Figarella-Branger D. Evidence for new targets and synergistic effect of metronomic celecoxib/fluvastatin combination in pilocytic astrocytoma. Acta Neuropathologica Communications. 1: 17. PMID 24252689 DOI: 10.1186/2051-5960-1-17  0.782
2013 Bouvier C, Bertucci F, Métellus P, Finetti P, Maues de Paula A, Forest F, Mokhtari K, Miquel C, Birnbaum D, Vasiljevic A, Jouvet A, Coindre JM, Loundou A, Figarella-Branger D. ALDH1 is an immunohistochemical diagnostic marker for solitary fibrous tumours and haemangiopericytomas of the meninges emerging from gene profiling study Acta Neuropathologica Communications. 1: 10. PMID 24252471 DOI: 10.1186/2051-5960-1-10  0.611
2013 Jaffrain-Rea ML, Rotondi S, Turchi A, Occhi G, Barlier A, Peverelli E, Rostomyan L, Defilles C, Angelini M, Oliva MA, Ceccato F, Maiorani O, Daly AF, Esposito V, Buttarelli F, ... Figarella-Branger D, et al. Somatostatin analogues increase AIP expression in somatotropinomas, irrespective of Gsp mutations. Endocrine-Related Cancer. 20: 753-66. PMID 23940012 DOI: 10.1530/Erc-12-0322  0.339
2013 Figarella-Branger D, Chappe C, Padovani L, Mercurio S, Colin C, Forest F, Bouvier C. [Glial and glioneuronal tumors in adults and children: main genetic alterations and towards a histomolecular classification]. Bulletin Du Cancer. 100: 715-26. PMID 23831947 DOI: 10.1684/Bdc.2013.1789  0.805
2013 Bertucci F, Bouvier-Labit C, Finetti P, Metellus P, Adelaide J, Mokhtari K, Figarella-Branger D, Decouvelaere AV, Miquel C, Coindre JM, Birnbaum D. Gene Expression Profiling of Solitary Fibrous Tumors Plos One. 8. PMID 23734203 DOI: 10.1371/Journal.Pone.0064497  0.374
2013 Tabouret E, Metellus P, Tallet-Richard A, Figarella-Branger D, Charaffe-Jauffret E, Viens P, Gonçalves A. Surgical resection of brain metastases from breast cancer in the modern era: clinical outcome and prognostic factors. Anticancer Research. 33: 2159-67. PMID 23645770  0.513
2013 Bourdeaut F, Grison C, Maurage CA, Laquerriere A, Vasiljevic A, Delisle MB, Michalak S, Figarella-Branger D, Doz F, Richer W, Pierron G, Miquel C, Delattre O, Couturier J. MYC and MYCN amplification can be reliably assessed by aCGH in medulloblastoma. Cancer Genetics. 206: 124-9. PMID 23578955 DOI: 10.1016/J.Cancergen.2013.02.003  0.336
2013 Chappé C, Padovani L, Scavarda D, Forest F, Nanni-Metellus I, Loundou A, Mercurio S, Fina F, Lena G, Colin C, Figarella-Branger D. Dysembryoplastic neuroepithelial tumors share with pleomorphic xanthoastrocytomas and gangliogliomas BRAF(V600E) mutation and expression. Brain Pathology (Zurich, Switzerland). 23: 574-83. PMID 23442159 DOI: 10.1111/Bpa.12048  0.803
2013 Trouillas J, Roy P, Sturm N, Dantony E, Cortet-Rudelli C, Viennet G, Bonneville JF, Assaker R, Auger C, Brue T, Cornelius A, Dufour H, Jouanneau E, François P, Galland F, ... ... Figarella-Branger D, et al. A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathologica. 126: 123-35. PMID 23400299 DOI: 10.1007/S00401-013-1084-Y  0.348
2013 Ait-Belkacem R, Calligaris D, Sellami L, Villard C, Granjeaud S, Schembri T, Berenguer C, Ouafik L, Figarella-Branger D, Chinot O, Lafitte D. Tubulin isoforms identified in the brain by MALDI in-source decay Journal of Proteomics. 79: 172-179. PMID 23279932 DOI: 10.1016/J.Jprot.2012.11.026  0.311
2013 Colin C, Padovani L, Chappé C, Mercurio S, Scavarda D, Loundou A, Frassineti F, André N, Bouvier C, Korshunov A, Lena G, Figarella-Branger D. Outcome analysis of childhood pilocytic astrocytomas: a retrospective study of 148 cases at a single institution. Neuropathology and Applied Neurobiology. 39: 693-705. PMID 23278243 DOI: 10.1111/Nan.12013  0.768
2013 Fernandez C, Bardin N, De Paula AM, Salort-Campana E, Benyamine A, Franques J, Schleinitz N, Weiller PJ, Pouget J, Pellissier JF, Figarella-Branger D. Correlation of clinicoserologic and pathologic classifications of inflammatory myopathies: study of 178 cases and guidelines for diagnosis. Medicine. 92: 15-24. PMID 23269233 DOI: 10.1097/Md.0B013E31827Ebba1  0.597
2013 Bertucci F, Bouvier-Labit C, Finetti P, Adélaïde J, Metellus P, Mokhtari K, Decouvelaere AV, Miquel C, Jouvet A, Figarella-Branger D, Pedeutour F, Chaffanet M, Birnbaum D. Comprehensive genome characterization of solitary fibrous tumors using high-resolution array-based comparative genomic hybridization Genes Chromosomes and Cancer. 52: 156-164. PMID 23073997 DOI: 10.1002/Gcc.22015  0.318
2013 Vasiljevic A, Champier J, Figarella-Branger D, Wierinckx A, Jouvet A, Fèvre-Montange M. Molecular characterization of central neurocytomas: potential markers for tumor typing and progression. Neuropathology : Official Journal of the Japanese Society of Neuropathology. 33: 149-61. PMID 22816789 DOI: 10.1111/J.1440-1789.2012.01338.X  0.382
2013 Bauchet L, Darlix A, Zouaoui S, Virion JM, Rigau V, Daude HM, Blonski M, Reyes-Botero G, Bessaoud F, Tretarre B, Bauchet F, Capelle L, Fabbro M, Kerr C, Figarella-Branger D, et al. Heterogeneity in the geographic distribution of diffuse grade II and III gliomas in France. Journal of Clinical Oncology. 31: 2067-2067. DOI: 10.1200/Jco.2013.31.15_Suppl.2067  0.311
2013 Forest F, Bouvier C, Maues de Paula A, Figarella-Branger D. Esami citologico, istologico, immunoistochimico e genetico dei tumori del sistema nervoso centrale Emc - Neurologia. 13: 1-26. DOI: 10.1016/S1634-7072(13)66018-3  0.518
2013 Bouvier C, Paula AMd, Roche P-, Chagnaud C, Figarella-Branger D. Tumori del sistema nervoso periferico Emc - Neurologia. 13: 1-11. DOI: 10.1016/S1634-7072(13)64487-6  0.522
2013 Bouvier C, Maues de Paula A, Roche P, Chagnaud C, Figarella-Branger D. Tumeurs du système nerveux périphérique Emc - Neurologie. 10: 1-11. DOI: 10.1016/S0246-0378(12)58206-0  0.515
2012 Fellah S, Caudal D, De Paula AM, Dory-Lautrec P, Figarella-Branger D, Chinot O, Metellus P, Cozzone PJ, Confort-Gouny S, Ghattas B, Callot V, Girard N. Multimodal MR imaging (diffusion, perfusion, and spectroscopy): is it possible to distinguish oligodendroglial tumor grade and 1p/19q codeletion in the pretherapeutic diagnosis? Ajnr. American Journal of Neuroradiology. 34: 1326-33. PMID 23221948 DOI: 10.3174/Ajnr.A3352  0.392
2012 Figarella-Branger D, Labrousse F, Mohktari K. [Guidelines for adult diffuse gliomas WHO grade II, III and IV: pathology and biology. Société franc¸aise de neuropathologie . Réseau de neuro-oncologie pathologique]. Annales De Pathologie. 32: 318-27. PMID 23141938 DOI: 10.1016/J.Annpat.2012.09.228  0.344
2012 Idbaih A, Ducray F, Dehais C, Courdy C, Carpentier C, de Bernard S, Uro-Coste E, Mokhtari K, Jouvet A, Honnorat J, Chinot O, Ramirez C, Beauchesne P, Benouaich-Amiel A, Godard J, ... ... Figarella-Branger D, et al. SNP array analysis reveals novel genomic abnormalities including copy neutral loss of heterozygosity in anaplastic oligodendrogliomas. Plos One. 7: e45950. PMID 23071531 DOI: 10.1371/Journal.Pone.0045950  0.396
2012 Padovani L, Colin C, Fernandez C, Maues de Paula A, Mercurio S, Scavarda D, Frassineti F, Adélaïde J, Loundou A, Intagliata D, Bouvier C, Lena G, Birnbaum D, Girard N, Figarella-Branger D. Search for distinctive markers in DNT and cortical grade II glioma in children: same clinicopathological and molecular entities? Current Topics in Medicinal Chemistry. 12: 1683-92. PMID 22978341 DOI: 10.2174/156802612803531450  0.782
2012 Figarella-Branger D, Bouvier C, De Paula AM, Mokhtari K, Colin C, Loundou A, Chinot O, Metellus P. Molecular genetics of adult grade II gliomas: Towards a comprehensive tumor classification system Journal of Neuro-Oncology. 110: 205-213. PMID 22890969 DOI: 10.1007/S11060-012-0953-X  0.75
2012 Gonzalez-Aguilar A, Idbaih A, Boisselier B, Habbita N, Rossetto M, Laurenge A, Bruno A, Jouvet A, Polivka M, Adam C, Figarella-Branger D, Miquel C, Vital A, Ghesquières H, Gressin R, et al. Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 5203-11. PMID 22837180 DOI: 10.1158/1078-0432.Ccr-12-0845  0.311
2012 Fèvre Montange M, Vasiljevic A, Bergemer Fouquet AM, Bernier M, Champier J, Chrétien F, Figarella-Branger D, Kemeny JL, Lechapt-Zalcman E, Michalak S, Miquel C, Mokthari K, Pommepuy I, Quintin Roué I, Rousseau A, et al. Histopathologic and ultrastructural features and claudin expression in papillary tumors of the pineal region: a multicenter analysis. The American Journal of Surgical Pathology. 36: 916-28. PMID 22588068 DOI: 10.1097/Pas.0B013E31824B7114  0.404
2012 Raverot G, Castinetti F, Jouanneau E, Morange I, Figarella-Branger D, Dufour H, Trouillas J, Brue T. Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment. Clinical Endocrinology. 76: 769-75. PMID 22404748 DOI: 10.1111/J.1365-2265.2012.04381.X  0.309
2012 Zouaoui S, Rigau V, Mathieu-Daudé H, Darlix A, Bessaoud F, Fabbro-Peray P, Bauchet F, Kerr C, Fabbro M, Figarella-Branger D, Taillandier L, Duffau H, Trétarre B, Bauchet L, et al. [French brain tumor database: general results on 40,000 cases, main current applications and future prospects]. Neuro-Chirurgie. 58: 4-13. PMID 22385800 DOI: 10.1016/J.Neuchi.2012.01.004  0.348
2012 Colavolpe C, Chinot O, Metellus P, Mancini J, Barrie M, Bequet-Boucard C, Tabouret E, Mundler O, Figarella-Branger D, Guedj E. FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan Neuro-Oncology. 14: 649-657. PMID 22379188 DOI: 10.1093/Neuonc/Nos012  0.592
2012 Devisme L, Bouchet C, Gonzalès M, Alanio E, Bazin A, Bessières B, Bigi N, Blanchet P, Bonneau D, Bonnières M, Bucourt M, Carles D, Clarisse B, Delahaye S, Fallet-Bianco C, ... Figarella-Branger D, et al. Cobblestone lissencephaly: neuropathological subtypes and correlations with genes of dystroglycanopathies. Brain : a Journal of Neurology. 135: 469-82. PMID 22323514 DOI: 10.1093/Brain/Awr357  0.319
2012 Vasiljevic A, François P, Loundou A, Fèvre-Montange M, Jouvet A, Roche PH, Figarella-Branger D. Prognostic factors in central neurocytomas: a multicenter study of 71 cases. The American Journal of Surgical Pathology. 36: 220-7. PMID 22251941 DOI: 10.1097/Pas.0B013E31823B8232  0.385
2012 Metellus P, Figarella-Branger D. Magnetic resonance metabolic imaging of glioma. Science Translational Medicine. 4: 116ps1. PMID 22238331 DOI: 10.1126/Scitranslmed.3003591  0.395
2012 Colavolpe C, Metellus P, Mancini J, Barrie M, Béquet-Boucard C, Figarella-Branger D, Mundler O, Chinot O, Guedj E. Independent prognostic value of pre-treatment 18-FDG-PET in high-grade gliomas Journal of Neuro-Oncology. 107: 527-535. PMID 22169956 DOI: 10.1007/S11060-011-0771-6  0.325
2012 Bouvier C, Met́ellus P, De Paula AM, Vasiljevic A, Jouvet A, Guyotat J, Mokhtari K, Varlet P, Dufour H, Figarella-Branger D. Solitary fibrous tumors and hemangiopericytomas of the meninges: Overlapping pathological features and common prognostic factors suggest the same spectrum of tumors Brain Pathology. 22: 511-521. PMID 22082190 DOI: 10.1111/J.1750-3639.2011.00552.X  0.632
2012 Tchoghandjian A, Baeza-Kallee N, Beclin C, Metellus P, Colin C, Ducray F, Adélaïde J, Rougon G, Figarella-Branger D. Cortical and subventricular zone glioblastoma-derived stem-like cells display different molecular profiles and differential in vitro and in vivo properties. Annals of Surgical Oncology. 19: S608-19. PMID 21989663 DOI: 10.1245/S10434-011-2093-5  0.796
2012 Roche C, Rasolonjanahary R, Thirion S, Goddard I, Fusco A, Figarella-Branger D, Dufour H, Brue T, Franc JL, Enjalbert A, Barlier A. Inactivation of transcription factor pit-1 to target tumoral somatolactotroph cells Human Gene Therapy. 23: 104-114. PMID 21942649 DOI: 10.1089/Hum.2011.105  0.383
2012 Fèvre-Montange M, Vasiljevic A, Frappaz D, Champier J, Szathmari A, Aubriot Lorton MH, Chapon F, Coulon A, Quintin Roué I, Delisle MB, Figarella-Branger D, Laquerrière A, Miquel C, Michiels JF, Péoch M, et al. Utility of Ki67 immunostaining in the grading of pineal parenchymal tumours: a multicentre study. Neuropathology and Applied Neurobiology. 38: 87-94. PMID 21696422 DOI: 10.1111/J.1365-2990.2011.01202.X  0.341
2012 Gonzalez A, Idbaih A, Boisselier B, Jouvet A, Polivka M, Adam C, Figarella-Branger D, Miquel C, Vital A, Ghesquieres H, Gressin R, Delwail V, Taillandier L, Chinot OL, Soubeyran P, et al. Recurrent genetic alterations in primary central nervous system lymphoma of immunocompetent patients. Journal of Clinical Oncology. 30: 2023-2023. DOI: 10.1200/Jco.2012.30.15_Suppl.2023  0.339
2012 Tabouret E, Metellus P, Tallet A, Figarella-Branger D, Charaffe-Jauffret E, Viens P, Gonçalves A. Abstract P3-12-11: Clinical outcome in patients with surgically resected brain metastases from breast cancer: prognostic considerations regarding molecular status and established prognostic classification systems. Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P3-12-11  0.361
2012 Barlier A, Graillon T, Defilles C, Mohamed A, Saveanu A, Figarella-Branger D, Chinot O, Roche P, Enjalbert A, Dufour H. Strong Additive Effect of Everolimus and Octreotide or Pasireotide on Meningioma Cells in Vitro: A New Therapeutic Strategy for These Tumors Annals of Oncology. 23. DOI: 10.1016/S0923-7534(20)33003-9  0.413
2012 Campana-Salort E, Franques J, Attarian S, Verschueren A, Maues de Paula A, Eymard B, Fernandez C, Suominen T, Penttilä S, Richard P, Monnier N, Lehtokari V, Wallgren-Pettersson C, Figarella-Branger D, Levy N, et al. Myopathies distales : à propos d’une étude rétrospective Revue Neurologique. 168: S15. DOI: 10.1016/S0035-3787(12)70029-2  0.577
2012 Metellus P, Bouvier C, Guyotat J, Adetchessi T, Jouvet A, Dufour H, Bertucci F, Fuentes S, Figarella-Branger D. ALDH1 est un marqueur diagnostique des tumeurs fibreuses solitaires des méninges Neurochirurgie. 58: 447. DOI: 10.1016/J.Neuchi.2012.10.125  0.513
2012 Compes P, Bouvier C, Adetchessi T, Dufour H, Fuentes S, Figarella-Branger D, Metellus P. Les tumeurs fibreuses solitaires et hémangio-péricytomes des méninges : un seul et même spectre tumoral ? Neurochirurgie. 58: 424. DOI: 10.1016/J.Neuchi.2012.10.050  0.558
2011 Metellus P, Coulibaly B, Colin C, Maues de Paula A, Barlier A, Loundou A, Fuentes S, Dufour H, Barrie M, Chinot OL, Ouafik L, Figarella-Branger D. Triple-negative, low-grade gliomas: A highly agressive tumor with dismal prognosis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2023. PMID 28023844 DOI: 10.1200/Jco.2011.29.15_Suppl.2023  0.796
2011 Metellus P, Colin C, Taieb D, Guedj E, Nanni-Metellus I, Coulibaly B, Colavolpe C, Fuentes S, Dufour H, Barrie M, Chinot OL, Ouafik L, Figarella-Branger D. IDH mutation status impact on in vivo hypoxia biomarkers expression: New insights from a clinical, nuclear imaging, and immunohistochemical study in 34 patients with glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2078. PMID 28019905 DOI: 10.1200/Jco.2011.29.15_Suppl.2078  0.795
2011 Figarella-Branger D, Paula AMd, Colin C, Bouvier C. Histomolecular classification of adult diffuse gliomas: the diagnostic value of immunohistochemical markers. Revue Neurologique. 167: 683-690. PMID 21889777 DOI: 10.1016/J.Neurol.2011.07.006  0.749
2011 Acunzo J, Roche C, Defilles C, Thirion S, Quentien MH, Figarella-Branger D, Graillon T, Dufour H, Brue T, Pellegrini I, Enjalbert A, Barlier A. Inactivation of PITX2 transcription factor induced apoptosis of gonadotroph tumoral cells. Endocrinology. 152: 3884-92. PMID 21810944 DOI: 10.1210/En.2011-1216  0.379
2011 Metellus P, Colin C, Taieb D, Guedj E, Nanni-Metellus I, De Paula AM, Colavolpe C, Fuentes S, Dufour H, Barrie M, Chinot O, Ouafik L, Figarella-Branger D. IDH mutation status impact on in vivo hypoxia biomarkers expression: New insights from a clinical, nuclear imaging and immunohistochemical study in 33 glioma patients Journal of Neuro-Oncology. 105: 591-600. PMID 21643985 DOI: 10.7490/F1000Research.2027.1  0.677
2011 Coulibaly B, Piercecchi-Marti MD, Fernandez C, Wasier AP, Viard L, Fraisse A, Figarella-Branger D, Leonetti G, Camboulives J, Paut O. [A rare cause of sudden cardiac failure: histiocytoid cardiomyopathy]. Annales De Pathologie. 31: 93-7. PMID 21601113 DOI: 10.1016/J.Annpat.2011.02.010  0.74
2011 Rigau V, Zouaoui S, Mathieu-Daudé H, Darlix A, Maran A, Trétarre B, Bessaoud F, Bauchet F, Attaoua R, Fabbro-Peray P, Fabbro M, Kerr C, Taillandier L, Duffau H, Figarella-Branger D, et al. French brain tumor database: 5-year histological results on 25 756 cases. Brain Pathology (Zurich, Switzerland). 21: 633-44. PMID 21554472 DOI: 10.1111/J.1750-3639.2011.00491.X  0.364
2011 Metellus P, Nanni-Metellus I, Delfino C, Colin C, Tchogandjian A, Coulibaly B, Fina F, Loundou A, Barrie M, Chinot O, Ouafik L, Figarella-Branger D. Prognostic impact of CD133 mRNA expression in 48 glioblastoma patients treated with concomitant radiochemotherapy: A prospective patient cohort at a single institution Annals of Surgical Oncology. 18: 2937-2945. PMID 21479688 DOI: 10.1245/S10434-011-1703-6  0.788
2011 Metellus P, Voutsinos-Porche B, Nanni-Metellus I, Colin C, Fina F, Berenguer C, Dussault N, Boudouresque F, Loundou A, Intagliata D, Chinot O, Martin PM, Figarella-Branger D, Ouafik L. Adrenomedullin expression and regulation in human glioblastoma, cultured human glioblastoma cell lines and pilocytic astrocytoma. European Journal of Cancer (Oxford, England : 1990). 47: 1727-35. PMID 21458987 DOI: 10.1016/J.Ejca.2011.02.021  0.639
2011 El Ayachi I, Fernandez C, Baeza N, De Paula AM, Pesheva P, Figarella-Branger D. Spatiotemporal distribution of tenascin-R in the developing human cerebral cortex parallels neuronal migration. The Journal of Comparative Neurology. 519: 2379-89. PMID 21456020 DOI: 10.1002/Cne.22632  0.573
2011 Coulibaly B, Bouvier C, Paula AM, Fernandez C, Dufour H, Figarella-Branger D. [Pituitary melanocytoma mimicking an adenoma]. Annales De Pathologie. 31: 50-2. PMID 21349390 DOI: 10.1016/J.Annpat.2010.09.007  0.771
2011 Bourdeaut F, Lequin D, Brugières L, Reynaud S, Dufour C, Doz F, André N, Stephan JL, Pérel Y, Oberlin O, Orbach D, Bergeron C, Rialland X, Fréneaux P, Ranchere D, ... Figarella-Branger D, et al. Frequent hSNF5/INI1 germline mutations in patients with rhabdoid tumor. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 31-8. PMID 21208904 DOI: 10.1158/1078-0432.Ccr-10-1795  0.363
2010 Raynaud S, Carbuccia N, Colin C, Adélaïde J, Mozziconacci MJ, Metellus P, Chinot O, Birnbaum D, Chaffanet M, Figarella-Branger D. Absence of R140Q mutation of isocitrate dehydrogenase 2 in gliomas and breast cancers. Oncology Letters. 1: 883-884. PMID 22966399 DOI: 10.3892/Ol_00000156  0.62
2010 Metellus P, Coulibaly B, Colin C, de Paula AM, Vasiljevic A, Taieb D, Barlier A, Boisselier B, Mokhtari K, Wang XW, Loundou A, Chapon F, Pineau S, Ouafik L, Chinot O, ... Figarella-Branger D, et al. Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathologica. 120: 719-29. PMID 21080178 DOI: 10.1007/S00401-010-0777-8  0.794
2010 Figarella-Branger D, Bouvier C, Moroch J, Michalak S, Burel-Vandenbos F. Classification morphologique des glioblastomes Neurochirurgie. 56: 459-463. PMID 20864138 DOI: 10.1016/J.Neuchi.2010.07.014  0.614
2010 Deville JL, Salas S, Figarella-Branger D, Ouafik L, Daniel L. Adrenomedullin as a therapeutic target in angiogenesis. Expert Opinion On Therapeutic Targets. 14: 1059-72. PMID 20846006 DOI: 10.1517/14728222.2010.522328  0.595
2010 Ducray F, de Reyniès A, Chinot O, Idbaih A, Figarella-Branger D, Colin C, Karayan-Tapon L, Chneiweiss H, Wager M, Vallette F, Marie Y, Rickman D, Thomas E, Delattre JY, Honnorat J, et al. An ANOCEF genomic and transcriptomic microarray study of the response to radiotherapy or to alkylating first-line chemotherapy in glioblastoma patients. Molecular Cancer. 9: 234. PMID 20822523 DOI: 10.1186/1476-4598-9-234  0.622
2010 Figarella-Branger D, Colin C, Tchoghandjian A, Baeza N, Bouvier C. [Glioblastomas: gliomagenesis, genetics, angiogenesis, and microenvironment]. Neuro-Chirurgie. 56: 441-8. PMID 20817192 DOI: 10.1016/J.Neuchi.2010.07.010  0.787
2010 Roussel-Gervais A, Bilodeau S, Vallette S, Berthelet F, Lacroix A, Figarella-Branger D, Brue T, Drouin J. Cooperation between cyclin E and p27(Kip1) in pituitary tumorigenesis. Molecular Endocrinology (Baltimore, Md.). 24: 1835-45. PMID 20660298 DOI: 10.1210/Me.2010-0091  0.333
2010 Raverot G, Sturm N, de Fraipont F, Muller M, Salenave S, Caron P, Chabre O, Chanson P, Cortet-Rudelli C, Assaker R, Dufour H, Gaillard S, François P, Jouanneau E, Passagia JG, ... ... Figarella-Branger D, et al. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. The Journal of Clinical Endocrinology and Metabolism. 95: 4592-9. PMID 20660056 DOI: 10.1210/Jc.2010-0644  0.349
2010 Uro-Soste E, Fernandez C, Authier FJ, Bassez G, Butori C, Chapon F, Delisle MB, Dubourg O, Feasson L, Gherardi R, Lacroix C, Laquerriere A, Letournel F, Magy L, Maisonobe T, ... ... Figarella-Branger D, et al. [Management of muscle and nerve biopsies: expert guidelines from two French professional societies, Société française de myologie et de l'Association française contre les myopathies]. Revue Neurologique. 166: 477-85. PMID 20626090 DOI: 10.1016/J.Neurol.2010.03.015  0.556
2010 Metellus P, Guyotat J, Chinot O, Durand A, Barrie M, Giorgi R, Jouvet A, Figarella-Branger D. Adult intracranial WHO grade II ependymomas: Long-term outcome and prognostic factor analysis in a series of 114 patients Neuro-Oncology. 12: 976-984. PMID 20484442 DOI: 10.1093/Neuonc/Noq047  0.404
2010 Bauchet L, Mathieu-Daudé H, Fabbro-Peray P, Rigau V, Fabbro M, Chinot O, Pallusseau L, Carnin C, Lainé K, Schlama A, Thiebaut A, Patru MC, Bauchet F, Lionnet M, Wager M, ... ... Figarella-Branger D, et al. Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004. Neuro-Oncology. 12: 725-35. PMID 20364023 DOI: 10.1093/Neuonc/Noq030  0.325
2010 Coulibaly B, Nanni I, Quilichini B, Gaudart J, Metellus P, Fina F, Boucard C, Chinot O, Ouafik L, Figarella-Branger D. Epidermal growth factor receptor in glioblastomas: correlation between gene copy number and protein expression Human Pathology. 41: 815-823. PMID 20303140 DOI: 10.1016/J.Humpath.2009.09.020  0.661
2010 Amoureux MC, Coulibaly B, Chinot O, Loundou A, Metellus P, Rougon G, Figarella-Branger D. Polysialic acid neural cell adhesion molecule (PSA-NCAM) is an adverse prognosis factor in glioblastoma, and regulates olig2 expression in glioma cell lines. Bmc Cancer. 10: 91. PMID 20219118 DOI: 10.1186/1471-2407-10-91  0.816
2010 Ayachi IE, Baeza N, Fernandez C, Colin C, Scavarda D, Pesheva P, Figarella-Branger D. KIAA0510, the 3'-untranslated region of the tenascin-R gene, and tenascin-R are overexpressed in pilocytic astrocytomas. Neuropathology and Applied Neurobiology. 36: 399-410. PMID 20202125 DOI: 10.1111/J.1365-2990.2010.01074.X  0.613
2010 Raverot G, Wierinckx A, Dantony E, Auger C, Chapas G, Villeneuve L, Brue T, Figarella-Branger D, Roy P, Jouanneau E, Jan M, Lachuer J, Trouillas J. Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up. The Journal of Clinical Endocrinology and Metabolism. 95: 1708-16. PMID 20164287 DOI: 10.1210/Jc.2009-1191  0.387
2010 Laigle-Donadey F, Figarella-Branger D, Chinot O, Taillandier L, Cartalat-Carel S, Honnorat J, Kaloshi G, Delattre JY, Sanson M. Up-front temozolomide in elderly patients with glioblastoma. Journal of Neuro-Oncology. 99: 89-94. PMID 20058048 DOI: 10.1007/S11060-009-0110-3  0.312
2010 Fernandez C, Halbert C, De Paula AM, Lacroze V, Froissart R, Figarella-Branger D, Chabrol B, Pellissier JF. Non-lethal neonatal neuromuscular variant of glycogenosis type IV with novel GBE1 mutations. Muscle & Nerve. 41: 269-71. PMID 19813197 DOI: 10.1002/Mus.21499  0.59
2010 Tchoghandjian A, Baeza N, Colin C, Cayre M, Metellus P, Beclin C, Ouafik L, Figarella-Branger D. A2B5 cells from human glioblastoma have cancer stem cell properties. Brain Pathology (Zurich, Switzerland). 20: 211-21. PMID 19243384 DOI: 10.1111/J.1750-3639.2009.00269.X  0.784
2010 Rigau V, Mathieu-Daude H, Figarella-Branger D, Tretarre B, Bauchet F, Fabbro M, Attaoua R, Chinot OL, Duffau H, Bauchet L. French Brain Tumor Data Bank (FBTDB): Main results on 23,648 cases. Journal of Clinical Oncology. 28: e12536-e12536. DOI: 10.1200/Jco.2010.28.15_Suppl.E12536  0.388
2010 Metellus P, Nanni-Metellus I, Delfino C, Colin C, Coulibaly B, Fina F, Chinot OL, Figarella-Branger D, Ouafik L. Prognostic impact of stem cell marker CD133 in 61 glioblastoma patients treated with concomitant chemoradiation: A prospective study. Journal of Clinical Oncology. 28: 2027-2027. DOI: 10.1200/Jco.2010.28.15_Suppl.2027  0.77
2010 Fernandez C, Halbert C, Paula AMd, Figarella-Branger D, Chabrol B, Pellissier J-. Dystrophies musculaires liées au gène DMD : myopathie de Duchenne, myopathie de Becker, formes féminine et atypiques Emc - Neurologie. 7: 1-15. DOI: 10.1016/S0246-0378(10)43869-5  0.559
2010 Jean E, Benarous L, Hubert A-, Ebbo M, Thomas G, Bernit E, Veit V, Figarella-Branger D, Daniel L, Valleix S, Harle J-, Schleinitz N. Amylose à lysozyme : description d’une nouvelle famille Revue De MéDecine Interne. 31. DOI: 10.1016/J.Revmed.2010.03.161  0.497
2010 Metellus P, Coulibaly B, Colin C, Marie Y, Boisselier B, Moktari K, Loundou A, Chapon F, Chinot O, Figarella-Branger D. L’absence de mutation d’IDH identifie une nouvelle entité radio-clinique et moléculaire au sein des gliomes de bas grade (OMS II) Neurochirurgie. 56: 538-539. DOI: 10.1016/J.Neuchi.2010.10.045  0.757
2009 Colin C, Voutsinos-Porche B, Nanni I, Fina F, Metellus P, Intagliata D, Baeza N, Bouvier C, Delfino C, Loundou A, Chinot O, Lah T, Kos J, Martin PM, Ouafik L, ... Figarella-Branger D, et al. High expression of cathepsin B and plasminogen activator inhibitor type-1 are strong predictors of survival in glioblastomas. Acta Neuropathologica. 118: 745-54. PMID 19774387 DOI: 10.1007/S00401-009-0592-2  0.742
2009 Metellus P, Coulibaly B, Nanni I, Fina F, Eudes N, Giorgi R, Barrie M, Chinot O, Fuentes S, Dufour H, Ouafik L, Figarella-Branger D. Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: A prospective patient cohort Cancer. 115: 4783-4794. PMID 19637364 DOI: 10.1002/Cncr.24546  0.692
2009 Deville JL, Bartoli C, Berenguer C, Fernandez-Sauze S, Kaafarani I, Delfino C, Fina F, Salas S, Muracciole X, Mancini J, Lechevallier E, Martin PM, Figarella-Branger D, Ouafik L, Daniel L. Expression and role of adrenomedullin in renal tumors and value of its mRNA levels as prognostic factor in clear-cell renal carcinoma. International Journal of Cancer. Journal International Du Cancer. 125: 2307-15. PMID 19610056 DOI: 10.1002/Ijc.24568  0.591
2009 Delamarre E, Taboubi S, Mathieu S, Bérenguer C, Rigot V, Lissitzky JC, Figarella-Branger D, Ouafik L, Luis J. Expression of integrin alpha6beta1 enhances tumorigenesis in glioma cells. The American Journal of Pathology. 175: 844-55. PMID 19574430 DOI: 10.2353/Ajpath.2009.080920  0.393
2009 De Paula AM, Franques J, Fernandez C, Monnier N, Lunardi J, Pellissier JF, Figarella-Branger D, Pouget J. A TPM3 mutation causing cap myopathy. Neuromuscular Disorders : Nmd. 19: 685-8. PMID 19553118 DOI: 10.1016/J.Nmd.2009.06.365  0.594
2009 Kaafarani I, Fernandez-Sauze S, Berenguer C, Chinot O, Delfino C, Dussert C, Metellus P, Boudouresque F, Mabrouk K, Grisoli F, Figarella-Branger D, Martin PM, Ouafik L. Targeting adrenomedullin receptors with systemic delivery of neutralizing antibodies inhibits tumor angiogenesis and suppresses growth of human tumor xenografts in mice. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 23: 3424-35. PMID 19546305 DOI: 10.1096/Fj.08-127852  0.356
2009 Guyotat J, Metellus P, Giorgi R, Barrie M, Jouvet A, Fevre-Montange M, Chinot O, Durand A, Figarella-Branger D. Infratentorial ependymomas: Prognostic factors and outcome analysis in a multi-center retrospective series of 106 adult patients Acta Neurochirurgica. 151: 947-960. PMID 19499166 DOI: 10.1007/S00701-009-0417-Z  0.364
2009 Salas S, Jézéquel P, Campion L, Deville JL, Chibon F, Bartoli C, Gentet JC, Charbonnel C, Gouraud W, Voutsinos-Porche B, Brouchet A, Duffaud F, Figarella-Branger D, Bouvier C. Molecular characterization of the response to chemotherapy in conventional osteosarcomas: predictive value of HSD17B10 and IFITM2. International Journal of Cancer. 125: 851-60. PMID 19449377 DOI: 10.1002/Ijc.24457  0.603
2009 Tchoghandjian A, Fernandez C, Colin C, El Ayachi I, Voutsinos-Porche B, Fina F, Scavarda D, Piercecchi-Marti MD, Intagliata D, Ouafik L, Fraslon-Vanhulle C, Figarella-Branger D. Pilocytic astrocytoma of the optic pathway: a tumour deriving from radial glia cells with a specific gene signature. Brain : a Journal of Neurology. 132: 1523-35. PMID 19336457 DOI: 10.1093/Brain/Awp048  0.801
2009 Carrie C, Grill J, Figarella-Branger D, Bernier V, Padovani L, Habrand JL, Benhassel M, Mege M, Mahé M, Quetin P, Maire JP, Baron MH, Clavere P, Chapet S, Maingon P, et al. Online quality control, hyperfractionated radiotherapy alone and reduced boost volume for standard risk medulloblastoma: Long-term results of MSFOP 98 Journal of Clinical Oncology. 27: 1879-1883. PMID 19273707 DOI: 10.1200/Jco.2008.18.6437  0.54
2009 Bauchet L, Rigau V, Mathieu-Daudé H, Fabbro-Peray P, Palenzuela G, Figarella-Branger D, Moritz J, Puget S, Bauchet F, Pallusseau L, Duffau H, Coubes P, Trétarre B, Labrousse F, Dhellemmes P, et al. Clinical epidemiology for childhood primary central nervous system tumors. Journal of Neuro-Oncology. 92: 87-98. PMID 19020806 DOI: 10.1007/S11060-008-9740-0  0.383
2009 Krahn M, Béroud C, Labelle V, Nguyen K, Bernard R, Bassez G, Figarella-Branger D, Fernandez C, Bouvenot J, Richard I, Ollagnon-Roman E, Bevilacqua JA, Salvo E, Attarian S, Chapon F, et al. Analysis of the DYSF mutational spectrum in a large cohort of patients. Human Mutation. 30: E345-75. PMID 18853459 DOI: 10.1002/Humu.20910  0.607
2009 Franques J, Campana-Salort E, Attarian S, Verschueren A, Fernandez C, Paula AMd, Figarella-Branger D, Pouget J. G.P.5.01 Retrospective study of 29 cases of distal myopathies Neuromuscular Disorders. 19: 567-568. DOI: 10.1016/J.Nmd.2009.06.079  0.573
2009 Padovani L, Leseur J, André N, Figarella-Branger D, Lena G, Frappaz D, Gentet J, Carrie C, Cowen D, Muracciole X. Pediatric Medulloblastoma: Educational Long-term Outcome and Clinical Factors International Journal of Radiation Oncology Biology Physics. 75. DOI: 10.1016/J.Ijrobp.2009.07.1177  0.527
2008 Roche PH, Bouvier C, Chinot O, Figarella-Branger D. Genesis and biology of vestibular schwannomas. Progress in Neurological Surgery. 21: 24-31. PMID 18810196 DOI: 10.1159/000156556  0.567
2008 Metellus P, Nanni I, Dussert C, Trinkhaus M, Fuentes S, Chinot O, Ouafik LH, Fina F, Dufour H, Figarella-Branger D, Grisoli F, Lah TT, Martin PM. [Prognostic implications of biologic markers in intracranial meningiomas: 120 cases]. Neuro-Chirurgie. 54: 750-6. PMID 18760426 DOI: 10.1016/J.Neuchi.2008.07.005  0.339
2008 Metellus P, Dutertre G, Mekkaoui C, Nanni I, Fuentes S, Ait-Ameur A, Chinot O, Dufour H, Figarella-Branger D, Cordoliani Y-, Grisoli F. Intérêt de la mesure du volume sanguin régional cérébral relatif par IRM de perfusion dans la prise en charge des gliomes Neurochirurgie. 54: 503-511. PMID 18573509 DOI: 10.1016/J.Neuchi.2008.03.007  0.327
2008 Figarella-Branger D, Colin C, Coulibaly B, Quilichini B, Maues De Paula A, Fernandez C, Bouvier C. [Histological and molecular classification of gliomas]. Revue Neurologique. 164: 505-15. PMID 18565348 DOI: 10.1016/J.Neurol.2008.03.011  0.822
2008 Fèvre-Montange M, Szathmari A, Champier J, Mokhtari K, Chrétien F, Coulon A, Figarella-Branger D, Polivka M, Varlet P, Uro-Coste E, Fauchon F, Jouvet A. Pineocytoma and pineal parenchymal tumors of intermediate differentiation presenting cytologic pleomorphism: A multicenter study Brain Pathology. 18: 354-359. PMID 18371183 DOI: 10.1111/J.1750-3639.2008.00128.X  0.402
2008 Trouillas J, Labat-Moleur F, Sturm N, Kujas M, Heymann MF, Figarella-Branger D, Patey M, Mazucca M, Decullier E, Vergès B, Chabre O, Calender A. Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients. The American Journal of Surgical Pathology. 32: 534-43. PMID 18300794 DOI: 10.1097/Pas.0B013E31815Ade45  0.358
2008 Bouvier C, Paula AMD, Fernandez C, Quilichini B, Scavarda D, Gentet JC, Figarella-Branger D. Atypical teratoid/rhabdoid tumour: 7-year event-free survival with gross total resection and radiotherapy in a 7-year-old boy. Childs Nervous System. 24: 143-147. PMID 17968559 DOI: 10.1007/S00381-007-0438-Y  0.715
2008 Berenguer C, Boudouresque F, Dussert C, Daniel L, Muracciole X, Grino M, Rossi D, Mabrouk K, Figarella-Branger D, Martin PM, Ouafik L. Adrenomedullin, an autocrine/paracrine factor induced by androgen withdrawal, stimulates 'neuroendocrine phenotype' in LNCaP prostate tumor cells. Oncogene. 27: 506-18. PMID 17637748 DOI: 10.1038/Sj.Onc.1210656  0.585
2008 Fernandez C, Soulier M, Coulibaly B, Liprandi A, Benoit B, Giuliano F, Sigaudy S, Figarella-Branger D, Fallet-Bianco C. Acrocallosal syndrome in fetus: focus on additional brain abnormalities. Acta Neuropathologica. 115: 151-6. PMID 17593378 DOI: 10.1007/S00401-007-0249-Y  0.747
2008 Chinot OL, Sanson M, Barrié M, Fabbro M, Taillandier L, Honnorat J, Figarella-Branger D, Mokhtari K, Guillevin R, Hoang-Xuan K. Phase II study of combination BCNU and temozolomide (TMZ) prior to radiotherapy in newly diagnosed anaplastic oligodendroglial tumors Journal of Clinical Oncology. 26: 2068-2068. DOI: 10.1200/Jco.2008.26.15_Suppl.2068  0.327
2008 Metellus P, Nanni I, Coulibaly B, Fina F, Eudes N, Figarella-Branger D, Chinot OL. Impact of MGMT silencing in patients harboring recurrent glioblastoma multiforme treated with surgery and BCNU chemotherapy wafers implantation Journal of Clinical Oncology. 26: 11094-11094. DOI: 10.1200/Jco.2008.26.15_Suppl.11094  0.691
2008 Fernandez C, Maues De Paula A, Figarella-Branger D, Chabrol B, Pouget J, Pellissier J. Intérêt de la biopsie musculaire dans l’exploration des hyperCKémies chroniques isolées Revue Du Rhumatisme. 75: 126-129. DOI: 10.1016/J.Rhum.2007.11.002  0.558
2008 Metellus P, Nanni I, Coulibaly B, Fuentes S, Chinot O, Tchogandjian A, Dufour H, Figarella-Branger D. Signification de la pseudoprogression chez les patients atteints de glioblastome traités par implantation de Gliadel® et corrélation au statut MGMT Neurochirurgie. 54: 693. DOI: 10.1016/J.Neuchi.2008.08.093  0.644
2007 Wierinckx A, Auger C, Devauchelle P, Reynaud A, Chevallier P, Jan M, Perrin G, Fèvre-Montange M, Rey C, Figarella-Branger D, Raverot G, Belin MF, Lachuer J, Trouillas J. A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumors. Endocrine-Related Cancer. 14: 887-900. PMID 17914117 DOI: 10.1677/Erc-07-0062  0.407
2007 Salas S, Bartoli C, Deville JL, Gaudart J, Fina F, Calisti A, Bollini G, Curvale G, Gentet JC, Duffaud F, Figarella-Branger D, Bouvier C. Ezrin and alpha-smooth muscle actin are immunohistochemical prognostic markers in conventional osteosarcomas. Virchows Archiv : An International Journal of Pathology. 451: 999-1007. PMID 17786474 DOI: 10.1007/S00428-007-0474-8  0.578
2007 Rousseau E, Palm T, Scaravilli F, Ruchoux MM, Figarella-Branger D, Salmon I, Ellison D, Lacroix C, Chapon F, Mikol J, Vikkula M, Godfraind C. Trisomy 19 ependymoma, a newly recognized genetico-histological association, including clear cell ependymoma. Molecular Cancer. 6: 47. PMID 17626628 DOI: 10.1186/1476-4598-6-47  0.397
2007 Kros JM, Gorlia T, Kouwenhoven MC, Zheng PP, Collins VP, Figarella-Branger D, Giangaspero F, Giannini C, Mokhtari K, Mørk SJ, Paetau A, Reifenberger G, van den Bent MJ. Panel review of anaplastic oligodendroglioma from European Organization For Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome. Journal of Neuropathology and Experimental Neurology. 66: 545-51. PMID 17549014 DOI: 10.1097/01.Jnen.0000263869.84188.72  0.365
2007 Picard C, Silvy M, Gerard C, Buffat C, Lavaque E, Figarella-Branger D, Dufour H, Gabert J, Beckers A, Brue T, Enjalbert A, Barlier A. Gs alpha overexpression and loss of Gs alpha imprinting in human somatotroph adenomas: association with tumor size and response to pharmacologic treatment. International Journal of Cancer. 121: 1245-1252. PMID 17514647 DOI: 10.1002/Ijc.22816  0.352
2007 Metellus P, Barrie M, Figarella-Branger D, Chinot O, Giorgi R, Jouvet A, Guyotat J. Intracranial ependymomas in adult patients. Retrospective analysis of 121 cases from the Multicentric French Study Neurochirurgie. 53: 66-75. PMID 17475290 DOI: 10.1016/J.Neuchi.2006.11.006  0.374
2007 Metellus P, Barrie M, Figarella-Branger D, Chinot O, Giorgi R, Gouvernet J, Jouvet A, Guyotat J. Multicentric French study on adult intracranial ependymomas: Prognostic factors analysis and therapeutic considerations from a cohort of 152 patients Brain. 130: 1338-1349. PMID 17449478 DOI: 10.1093/Brain/Awm046  0.369
2007 Figarella-Branger D, Metellus P, Barrié M, Maues de Paula A, Fernandez C, Polivka M, Vital A, Labrousse F, Vignaud JM, Laquerrière A, Rousselet MC, Lacroix C, Saikali S, Chapon F, Gontier MF, et al. [Intracranial ependymomas in adult patients. Diagnosis and histological prognostic factors]. Neuro-Chirurgie. 53: 76-84. PMID 17445840 DOI: 10.1016/J.Neuchi.2006.11.007  0.643
2007 Chinot OL, Barrié M, Fuentes S, Eudes N, Lancelot S, Metellus P, Muracciole X, Braguer D, Ouafik L, Martin PM, Dufour H, Figarella-Branger D. Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 1470-5. PMID 17442989 DOI: 10.1200/Jco.2006.07.4807  0.324
2007 Colin C, Virard I, Baeza N, Tchoghandjian A, Fernandez C, Bouvier C, Calisti A, Tong S, Durbec P, Figarella-Branger D. Relevance of combinatorial profiles of intermediate filaments and transcription factors for glioma histogenesis. Neuropathology and Applied Neurobiology. 33: 431-9. PMID 17442061 DOI: 10.1111/J.1365-2990.2007.00829.X  0.795
2007 Bauchet L, Rigau V, Mathieu-Daudé H, Figarella-Branger D, Hugues D, Palusseau L, Bauchet F, Fabbro M, Campello C, Capelle L, Durand A, Trétarre B, Frappaz D, Henin D, Menei P, et al. French brain tumor data bank: methodology and first results on 10,000 cases. Journal of Neuro-Oncology. 84: 189-99. PMID 17431547 DOI: 10.1007/S11060-007-9356-9  0.36
2007 Metellus P, Bouvier C, Guyotat J, Fuentes S, Jouvet A, Vasiljevic A, Giorgi R, Dufour H, Grisoli F, Figarella-Branger D. Solitary fibrous tumors of the central nervous system: clinicopathological and therapeutic considerations of 18 cases. Neurosurgery. 60: 715-22; discussion 7. PMID 17415209 DOI: 10.1227/01.Neu.0000255418.93678.Ad  0.612
2007 Schneider JF, Viola A, Confort-Gouny S, Ayunts K, Fur YL, Viout P, Bennathan M, Chapon F, Figarella-Branger D, Cozzone P, Girard N. Infratentorial pediatric brain tumors: the value of new imaging modalities Journal of Neuroradiology. 34: 49-58. PMID 17316798 DOI: 10.1016/J.Neurad.2007.01.010  0.331
2007 Cantagrel V, Lossi AM, Lisgo S, Missirian C, Borges A, Philip N, Fernandez C, Cardoso C, Figarella-Branger D, Moncla A, Lindsay S, Dobyns WB, Villard L. Truncation of NHEJ1 in a patient with polymicrogyria. Human Mutation. 28: 356-64. PMID 17191205 DOI: 10.1002/Humu.20450  0.613
2007 Deville J, Salas S, Bartoli C, Dupuis C, Duffaud F, Sebahoun G, Figarella-Branger D, Ouafik L, Martin P, Daniel L. Adrenomedullin and its receptors expression in renal tumors Journal of Clinical Oncology. 25: 10568-10568. DOI: 10.1200/Jco.2007.25.18_Suppl.10568  0.337
2007 Salas S, Deville J, Bartoli C, Gaudart J, Bollini G, Curvale G, Gentet J, Duffaud F, Figarella-Branger D, Bouvier C. Immunohistochemical expression of ezrin correlates with Event-free and overall survival in osteosarcomas Journal of Clinical Oncology. 25: 10035-10035. DOI: 10.1200/Jco.2007.25.18_Suppl.10035  0.627
2007 Figarella-Branger D, Fernandez C, Maues de Paula A, Pellissier J. Pièges diagnostiques dans les myopathies inflammatoires Revue Neurologique. 163: 217. DOI: 10.1016/S0035-3787(07)90912-1  0.555
2007 Bouvier C, Salas S, Gaudart J, Bollini G, Curvale G, Gentet J, Duffaud F, Figarella-Branger D. Expression de l’ezrine dans les ostéosarcomes centraux de haut grade : corrélations pronostiques Revue De Chirurgie OrthopéDique Et RéParatrice De L'Appareil Moteur. 93: 758. DOI: 10.1016/S0035-1040(07)73275-0  0.57
2007 Metellus P, Nanni I, Coulibaly B, Fuentes S, Chinot O, Éudes N, Baeza N, Dufour H, Figarella-Branger D. Impact pronostique de marqueurs de chimiorésistance dans les glioblastomes récidivants traités par chirurgie et implantation de Gliadel® Neurochirurgie. 53: 424. DOI: 10.1016/J.Neuchi.2007.09.035  0.635
2006 Fèvre-Montange M, Hasselblatt M, Figarella-Branger D, Chauveinc L, Champier J, Saint-Pierre G, Taillandier L, Coulon A, Paulus W, Fauchon F, Jouvet A. Prognosis and histopathologic features in papillary tumors of the pineal region: a retrospective multicenter study of 31 cases. Journal of Neuropathology and Experimental Neurology. 65: 1004-11. PMID 17021405 DOI: 10.1097/01.Jnen.0000240462.80263.13  0.429
2006 Fernandez C, Maues de Paula A, Colin C, Quilichini B, Bouvier-Labit C, Girard N, Scavarda D, Lena G, Figarella-Branger D. Thalamic gliomas in children: an extensive clinical, neuroradiological and pathological study of 14 cases. Child's Nervous System : Chns : Official Journal of the International Society For Pediatric Neurosurgery. 22: 1603-10. PMID 16951965 DOI: 10.1007/S00381-006-0184-6  0.74
2006 Fèvre-Montange M, Champier J, Szathmari A, Wierinckx A, Mottolese C, Guyotat J, Figarella-Branger D, Jouvet A, Lachuer J. Microarray analysis reveals differential gene expression patterns in tumors of the pineal region. Journal of Neuropathology and Experimental Neurology. 65: 675-84. PMID 16825954 DOI: 10.1097/01.Jnen.0000225907.90052.E3  0.389
2006 Fernandez C, De Paula AM, Figarella-Branger D, Krahn M, Giorgi R, Chabrol B, Monfort MF, Pouget J, Pellissier JF. Diagnostic evaluation of clinically normal subjects with chronic hyperCKemia Neurology. 66: 1585-1587. PMID 16717227 DOI: 10.1212/01.Wnl.0000216144.69630.6E  0.574
2006 Figarella-Branger D, Colin C, Chinot O, Nanni I, Baeza N, Fina F, Tong S, Eudes N, Quilichini B, Romain S, Metellus P, Fuentes S, Barrié M, Boucard C, Fraslon C, et al. AP-HM tumour tissue bank: Molecular signature of gliomas | Tumorothèque de l'AP-HM: Cartographie moléculaire des gliomes Medecine/Sciences. 22: 54-59. PMID 16705945 DOI: 10.1051/Medsci/2006221S54  0.681
2006 Galanaud D, Nicoli F, Chinot O, Confort-Gouny S, Figarella-Branger D, Roche P, Fuentès S, Le Fur Y, Ranjeva JP, Cozzone PJ. Noninvasive diagnostic assessment of brain tumors using combined in vivo MR imaging and spectroscopy. Magnetic Resonance in Medicine. 55: 1236-45. PMID 16680716 DOI: 10.1002/Mrm.20886  0.341
2006 Colin C, Baeza N, Tong S, Bouvier C, Quilichini B, Durbec P, Figarella-Branger D. In vitro identification and functional characterization of glial precursor cells in human gliomas. Neuropathology and Applied Neurobiology. 32: 189-202. PMID 16599947 DOI: 10.1111/J.1365-2990.2006.00740.X  0.729
2006 Figarella-Branger D, Trouillas J. The new WHO classification of human pituitary tumors: comments. Acta Neuropathologica. 111: 71-72. PMID 16328522 DOI: 10.1007/S00401-005-1099-0  0.413
2006 Kababri ME, André N, Carole C, Lena G, Figarella-Branger D, Gentet JC. Atypical teratoid rhabdoid tumor in a child with neurofibromatosis 1. Pediatric Blood & Cancer. 46: 267-268. PMID 16086409 DOI: 10.1002/Pbc.20535  0.33
2006 Deville JL, Bartoli C, Fina F, Salas S, Lechevallier E, Martin PM, Figarella-branger D, Ouafik L, Daniel L. Expression de l’adrénomédulline dans les cancers du rein Annales De Pathologie. 26: 136. DOI: 10.1016/S0242-6498(06)78450-4  0.528
2006 Guerroui N, Mattei J, Bendahan D, Fernandez C, Figarella-Branger D, Levy N, Pellissier J, Cozzone P, Roudier J, Guis S. Trois classes d'hypolipémiants pourvoyeuses de myalgies chez un patient Revue Du Rhumatisme. 73: 1102-1103. DOI: 10.1016/J.Rhum.2006.10.200  0.563
2005 Galanaud D, Nicoli F, Figarella-Branger D, Roche P, Confort-Gouny S, Fur YL, Cozzone PJ. Spectroscopie par résonance magnétique des tumeurs cérébrales Journal De Radiologie. 87: 822-832. PMID 16778750 DOI: 10.1016/S0221-0363(06)74090-2  0.37
2005 Fernandez C, Figarella-Branger D, Meyronet D, Cassote E, Tong S, Pellissier JF. Electron microscopy in neuromuscular disorders. Ultrastructural Pathology. 29: 437-50. PMID 16316944 DOI: 10.1080/01913120500323175  0.579
2005 Monnier N, Kozak-Ribbens G, Krivosic-Horber R, Nivoche Y, Qi D, Kraev N, Loke J, Sharma P, Tegazzin V, Figarella-Branger D, Roméro N, Mezin P, Bendahan D, Payen JF, Depret T, et al. Correlations between genotype and pharmacological, histological, functional, and clinical phenotypes in malignant hyperthermia susceptibility. Human Mutation. 26: 413-25. PMID 16163667 DOI: 10.1002/Humu.20231  0.31
2005 Bouvier C, Liprandi A, Colin C, Giorgi R, Quilichini B, Metellus P, Figarella-Branger D. Lack of alkaline phosphatase activity predicts meningioma recurrence. American Journal of Clinical Pathology. 124: 252-8. PMID 16040297 DOI: 10.1309/482Awa3U8Djuexwu  0.756
2005 Figarella-Branger D, Bouvier C. [Histological classification of human gliomas: state of art and controversies]. Bulletin Du Cancer. 92: 301-9. PMID 15888386  0.565
2005 Barrié M, Couprie C, Dufour H, Figarella-Branger D, Muracciole X, Hoang-Xuan K, Braguer D, Martin PM, Peragut JC, Grisoli F, Chinot O. Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme Annals of Oncology. 16: 1177-1184. PMID 15857844 DOI: 10.1093/Annonc/Mdi225  0.321
2005 Fogliarini C, Chaumoitre K, Chapon F, Fernandez C, Lévrier O, Figarella-Branger D, Girard N. Assessment of cortical maturation with prenatal MRI. Part I: Normal cortical maturation. European Radiology. 15: 1671-85. PMID 15856237 DOI: 10.1007/S00330-005-2782-1  0.572
2005 Fogliarini C, Chaumoitre K, Chapon F, Fernandez C, Lévrier O, Figarella-Branger D, Girard N. Assessment of cortical maturation with prenatal MRI: part II: abnormalities of cortical maturation. European Radiology. 15: 1781-9. PMID 15843935 DOI: 10.1016/J.Clinimag.2005.12.003  0.576
2005 Daniel L, Bardin N, Moal V, Dignat-George F, Berland Y, Figarella-Branger D. Tubular CD146 expression in nephropathies is related to chronic renal failure. Nephron. Experimental Nephrology. 99: e105-11. PMID 15703461 DOI: 10.1159/000083890  0.516
2005 Sáenz A, Leturcq F, Cobo AM, Poza JJ, Ferrer X, Otaegui D, Camaño P, Urtasun M, Vílchez J, Gutiérrez-Rivas E, Emparanza J, Merlini L, Paisán C, Goicoechea M, Blázquez L, ... ... Figarella-Branger D, et al. LGMD2A: genotype-phenotype correlations based on a large mutational survey on the calpain 3 gene. Brain : a Journal of Neurology. 128: 732-42. PMID 15689361 DOI: 10.1093/Brain/Awh408  0.311
2005 Bouvier C, Gavril C, Zattara H, Dufour H, Fuentes S, Graziani N, Figarella-Branger D. Les tumeurs fibreuses solitaires des méninges : à propos de 7 cas. Revue Neurologique. 161: 337. DOI: 10.1016/S0035-3787(05)85045-3  0.504
2005 Fogliarini C, Chaumoitre K, Chapon F, Fernandez C, Lévrier O, Figarella-Branger D, Girard N. Assessment of cortical maturation with prenatal MRI:Part I. Normal cortical maturation Clinical Imaging. 30: 146. DOI: 10.1016/J.Clinimag.2005.12.002  0.572
2004 Daniel L, Robert A, Lesavre P, Figarella-Branger D. Severe mesangiolysis in a patient exposed to glycol ether solvents. Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association. 19: 2679. PMID 15388836 DOI: 10.1093/Ndt/Gfh431  0.502
2004 Bouvier C, Roll P, Quilichini B, Metellus P, Calisti A, Gilles S, Chinot O, Fina F, Martin PM, Figarella-Branger D. Deletions of chromosomes 1p and 19q are detectable on frozen smears of gliomas by FISH: usefulness for stereotactic biopsies. Journal of Neuro-Oncology. 68: 141-9. PMID 15218950 DOI: 10.1023/B:Neon.0000027758.10286.C1  0.593
2004 Bouvier C, Roll P, Chinot O, Metellus P, Quilichini B, Calisti A, Martin P, Figarella-Branger D. Mise en évidence de délétions 1p/19q sur des smears congelés de gliomes en FISH Revue Neurologique. 160: 849. DOI: 10.1016/S0035-3787(04)71058-9  0.541
2003 Civatte M, Schleinitz N, Krammer PH, Fernandez C, Guis S, Veit V, Pouget J, Harlé JR, Pellissier JF, Figarella-Branger D. Class I MHC detection as a diagnostic tool in noninformative muscle biopsies of patients suffering from dermatomyositis (DM). Neuropathology and Applied Neurobiology. 29: 546-552. PMID 14636161 DOI: 10.1046/J.1365-2990.2003.00471.X  0.594
2003 Fernandez C, Figarella-Branger D, Girard N, Bouvier-Labit C, Gouvernet J, Paz Paredes A, Lena G. Pilocytic astrocytomas in children: prognostic factors--a retrospective study of 80 cases. Neurosurgery. 53: 544-53; discussion 5. PMID 12943571 DOI: 10.1227/01.Neu.0000079330.01541.6E  0.638
2003 Figarella-Branger D, Pouget J, Bernard R, Krahn M, Fernandez C, Lévy N, Pellissier JF. Limb-girdle muscular dystrophy in a 71-year-old woman with an R27Q mutation in the CAV3 gene Neurology. 61: 562-564. PMID 12939441 DOI: 10.1212/01.Wnl.0000076486.57572.5C  0.595
2003 Bouvier C, Bartoli C, Aguirre-Cruz L, Virard I, Colin C, Fernandez C, Gouvernet J, Figarella-Branger D. Shared oligodendrocyte lineage gene expression in gliomas and oligodendrocyte progenitor cells. Journal of Neurosurgery. 99: 344-50. PMID 12924709 DOI: 10.3171/Jns.2003.99.2.0344  0.808
2003 Daniel L, Bouvier C, Chetaille B, Gouvernet J, Luccioni A, Rossi D, Lechevallier E, Muracciole X, Coulange C, Figarella-Branger D. Neural cell adhesion molecule expression in renal cell carcinomas: relation to metastatic behavior. Human Pathology. 34: 528-32. PMID 12827605 DOI: 10.1016/S0046-8177(03)00178-3  0.711
2003 Fernandez C, Girard N, Paz Paredes A, Bouvier-Labit C, Lena G, Figarella-Branger D. The usefulness of MR imaging in the diagnosis of dysembryoplastic neuroepithelial tumor in children: a study of 14 cases. Ajnr. American Journal of Neuroradiology. 24: 829-34. PMID 12748079  0.571
2003 Trouillas J, Daniel L, Guigard MP, Tong S, Gouvernet J, Jouanneau E, Jan M, Perrin G, Fischer G, Tabarin A, Rougon G, Figarella-Branger D. Polysialylated neural cell adhesion molecules expressed in human pituitary tumors and related to extrasellar invasion. Journal of Neurosurgery. 98: 1084-93. PMID 12744370 DOI: 10.3171/Jns.2003.98.5.1084  0.776
2003 Galanaud D, Chinot O, Nicoli F, Confort-Gouny S, Le Fur Y, Barrie-Attarian M, Ranjeva JP, Fuentès S, Viout P, Figarella-Branger D, Cozzone PJ. Use of proton magnetic resonance spectroscopy of the brain to differentiate gliomatosis cerebri from low-grade glioma. Journal of Neurosurgery. 98: 269-76. PMID 12593610 DOI: 10.3171/Jns.2003.98.2.0269  0.306
2002 Bouvier-Labit C, Liprandi A, Monti G, Pellissier JF, Figarella-Branger D. CD44H is expressed by cells of the oligodendrocyte lineage and by oligodendrogliomas in humans. Journal of Neuro-Oncology. 60: 127-134. PMID 12635659 DOI: 10.1023/A:1020630732625  0.374
2002 Gavril C, Bouvier C, Liprandi A, Dufour H, Peragut JC, Zanaret M, Figarella-Branger D. [Pathology of myxoid bone tumors of the skull base]. Annales De Pathologie. 22: 259-66. PMID 12410148  0.571
2002 Peretti-Viton P, Brunel H, Chinot O, Daniel C, Barrié M, Bouvier C, Figarella-Branger D, Fuentes S, Dufour H, Grisoli F. Histological and MR correlations in Gliomatosis cerebri. Journal of Neuro-Oncology. 59: 249-59. PMID 12241123 DOI: 10.1023/A:1019934901750  0.602
2002 Lucas M, Daniel L, Tomasello E, Guia S, Horschowski N, Aoki N, Figarella-Branger D, Gomez S, Vivier E. Massive inflammatory syndrome and lymphocytic immunodeficiency in KARAP/DAP12-transgenic mice. European Journal of Immunology. 32: 2653-63. PMID 12207350 DOI: 10.1002/1521-4141(200209)32:9<2653::Aid-Immu2653>3.0.Co;2-V  0.515
2002 Fernandez C, Bouvier C, Sévenet N, Liprandi A, Coze C, Lena G, Figarella-Branger D. Congenital disseminated malignant rhabdoid tumor and cerebellar tumor mimicking medulloblastoma in monozygotic twins: pathologic and molecular diagnosis. The American Journal of Surgical Pathology. 26: 266-270. PMID 11812951 DOI: 10.1097/00000478-200202000-00016  0.615
2002 Daniel L, Sichez H, Giorgi R, Dussol B, Figarella-Branger D, Pellissier JF, Berland Y. Tubular lesions and tubular cell adhesion molecules for the prognosis of lupus nephritis. Kidney International. 60: 2215-21. PMID 11737595 DOI: 10.1046/J.1523-1755.2001.00055.X  0.55
2001 Fernandez C, Figarella-Branger D, Alla P, Harlé JR, Pellissier JF. Colchicine myopathy: a vacuolar myopathy with selective type I muscle fiber involvement. An immunohistochemical and electron microscopic study of two cases. Acta Neuropathologica. 103: 100-6. PMID 11810174 DOI: 10.1007/S004010100434  0.58
2001 Bartoli C, Civatte M, Pellissier JF, Figarella-Branger D. CCR2A and CCR2B, the two isoforms of the monocyte chemoattractant protein-1 receptor are up-regulated and expressed by different cell subsets in idiopathic inflammatory myopathies. Acta Neuropathologica. 102: 385-392. PMID 11603815 DOI: 10.1007/S004010100394  0.306
2001 Zattara-Cannoni H, Roll P, Figarella-Branger D, Lena G, Dufour H, Grisoli F, Vagner-Capodano AM. Cytogenetic study of six cases of radiation-induced meningiomas. Cancer Genetics and Cytogenetics. 126: 81-4. PMID 11376799 DOI: 10.1016/S0165-4608(00)00398-8  0.302
2001 Chinot OL, Honore S, Dufour H, Barrie M, Figarella-Branger D, Muracciole X, Braguer D, Martin PM, Grisoli F. Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy Journal of Clinical Oncology. 19: 2449-2455. PMID 11331324 DOI: 10.1200/Jco.2001.19.9.2449  0.326
2001 Daniel L, Durbec P, Gautherot E, Rouvier E, Rougon G, Figarella-Branger D. A nude mice model of human rhabdomyosarcoma lung metastases for evaluating the role of polysialic acids in the metastatic process. Oncogene. 20: 997-1004. PMID 11314035 DOI: 10.1038/Sj.Onc.1204176  0.594
2001 Daniel L, Lechevallier E, Giorgi R, Sichez H, Zattara-Cannoni H, Figarella-Branger D, Coulange C. Pax-2 expression in adult renal tumors*** Human Pathology. 32: 282-287. PMID 11274636 DOI: 10.1053/Hupa.2001.22753  0.594
2001 Daniel L, Lechevallier E, Giorgi R, Lindner V, De Fromont M, Vieillefond A, Coulange C, Figarella-Branger D. CD44s and CD44v6 expression in localized T1-T2 conventional renal cell carcinomas. The Journal of Pathology. 193: 345-9. PMID 11241414 DOI: 10.1002/1096-9896(2000)9999:9999<::Aid-Path817>3.0.Co;2-H  0.513
2000 Figarella-Branger D, Civatte M, Bouvier-Labit C, Gouvernet J, Gambarelli D, Gentet J, Lena G, Choux M, Pellissier JF. Prognostic factors in intracranial ependymomas in children. Journal of Neurosurgery. 93: 605-613. PMID 11014538 DOI: 10.3171/Jns.2000.93.4.0605  0.376
2000 Bouvier-Labit C, Daniel L, Dufour H, Grisoli F, Figarella-Branger D. Papillary glioneuronal tumour: clinicopathological and biochemical study of one case with 7-year follow up. Acta Neuropathologica. 99: 321-326. PMID 10663977 DOI: 10.1007/Pl00007445  0.323
2000 Vagner-Capodano AM, Zattara-Cannoni H, Gambarelli D, Figarella-Branger D, Lena G, Dufour H, Grisoli F, Choux M. Cytogenetic study of 33 ependymomas. Cancer Genetics and Cytogenetics. 115: 96-9. PMID 10598140 DOI: 10.1016/S0165-4608(99)00080-1  0.371
1999 Figarella-Branger D, Daniel L, André P, Guia S, Renaud W, Monti G, Vivier E, Rougon G. The PEN5 epitope identifies an oligodendrocyte precursor cell population and pilocytic astrocytomas. The American Journal of Pathology. 155: 1261-9. PMID 10514408 DOI: 10.1016/S0002-9440(10)65228-5  0.592
1999 Aroca F, Renaud W, Bartoli C, Bouvier-Labit C, Figarella-Branger D. Expression of PECAM-1/CD31 isoforms in human brain gliomas. Journal of Neuro-Oncology. 43: 19-25. PMID 10448867 DOI: 10.1023/A:1006233816724  0.357
1999 Pellegrini-Bouiller I, Manrique C, Gunz G, Grino M, Zamora AJ, Figarella-Branger D, Grisoli F, Jaquet P, Enjalbert A. Expression of the members of the Ptx family of transcription factors in human pituitary adenomas Journal of Clinical Endocrinology and Metabolism. 84: 2212-2220. PMID 10372733 DOI: 10.1210/Jcem.84.6.5760  0.359
1999 Donnet A, Figarella-Branger D, Grisoli F. Primary meningeal fibrosarcoma: a particular neuroradiological presentation. Journal of Neuro-Oncology. 42: 79-83. PMID 10360482 DOI: 10.1023/A:1006100119406  0.332
1998 Barlier A, Gunz G, Zamora AJ, Morange-Ramos I, Figarella-Branger D, Dufour H, Enjalbert A, Jaquet P. Pronostic and therapeutic consequences of Gs alpha mutations in somatotroph adenomas. The Journal of Clinical Endocrinology and Metabolism. 83: 1604-10. PMID 9589663 DOI: 10.1210/Jcem.83.5.4797  0.36
1998 Roche P, Dufour H, Figarella-Branger D, Pellet W. Endolymphatic sac tumors: report of three cases. Neurosurgery. 42: 927-932. PMID 9574660 DOI: 10.1097/00006123-199804000-00139  0.375
1997 Daniel L, Figarella-Branger D, Tournigand P, Hassoun J, Pellissier J. Sarcomes aortiques avec embolies périphériques: à propos de deux cas Revue De MéDecine Interne. 18: 799-805. PMID 9500014 DOI: 10.1016/S0248-8663(97)89970-5  0.507
1997 Roche PH, Figarella-Branger D, Daniel L, Bianco N, Pellet W, Pellissier JF. Expression of cell adhesion molecules in normal nerves, chronic axonal neuropathies and Schwann cell tumors. Journal of the Neurological Sciences. 151: 127-33. PMID 9349666 DOI: 10.1016/S0022-510X(97)00110-X  0.564
1997 Vagner-Capodano AM, Mugneret F, Zattara-Cannoni H, Gabert J, Favre B, Figarella-Branger D, Gentet JC, Lena G, Bernard JL. Translocation 1;19 in two brain tumors. Cancer Genetics and Cytogenetics. 97: 1-4. PMID 9242210 DOI: 10.1016/S0165-4608(96)00270-1  0.321
1997 Figarella-Branger D, Roche PH, Daniel L, Dufour H, Bianco N, Pellissier JF. Cell‐adhesion molecules in human meningiomas: correlation with clinical and morphological data Neuropathology and Applied Neurobiology. 23: 113-122. DOI: 10.1111/J.1365-2990.1997.Tb01193.X  0.555
1996 Poncet C, Frances V, Gristina R, Scheiner C, Pellissier JF, Figarella-Branger D. CD24, a glycosylphosphatidylinositol-anchored molecule, is transiently expressed during the development of human central nervous system and is a marker of human neural cell lineage tumors Acta Neuropathologica. 91: 400-408. PMID 8928617 DOI: 10.1007/S004010050442  0.352
1996 Regis J, Bouillot P, Rouby-Volot F, Figarella-Branger D, Dufour H, Peragut JC. Pineal Region Tumors and the Role of Stereotactic Biopsy: Review of the Mortality, Morbidity, and Diagnostic Rates in 370 Cases Neurosurgery. 39: 907-914. PMID 8905744 DOI: 10.1097/00006123-199611000-00003  0.317
1996 Zattara-Cannoni H, North MO, Gambarelli D, Figarella-Branger D, Graziani N, Grisoli F, Vagner-Capodano AM. The contribution of cytogenetics to the histogenesis of meningeal hemangiopericytoma. Journal of Neuro-Oncology. 29: 137-142. PMID 8858518 DOI: 10.1007/Bf00182136  0.333
1996 Pellegrini-Bouiller I, Morange-Ramos I, Barlier A, Gunz G, Figarella-Branger D, Cortet-Rudelli C, Grisoli F, Jaquet P, Enjalbert A. Pit-1 gene expression in human lactotroph and somatotroph pituitary adenomas is correlated to D2 receptor gene expression. The Journal of Clinical Endocrinology and Metabolism. 81: 3390-3396. PMID 8784102 DOI: 10.1210/Jcem.81.9.8784102  0.337
1995 Figarella-Branger D, Lepidi H, Poncet C, Gambarelli D, Bianco N, Rougon G, Pellissier J. Differential expression of cell adhesion molecules (CAM), neural CAM and epithelial cadherin in ependymomas and choroid plexus tumors Acta Neuropathologica. 89: 248-257. PMID 7754745 DOI: 10.1007/Bf00309340  0.381
1995 Dubois C, Okandze A, Figarella-Branger D, Rampini C, Rougon G. A monoclonal antibody against Meningococcus group B polysaccharides used to immunocapture and quantify polysialylated NCAM in tissues and biological fluids. Journal of Immunological Methods. 181: 125-135. PMID 7730661 DOI: 10.1016/0022-1759(94)00336-U  0.309
1994 Pellegrini I, Barlier A, Gunz G, Figarella-Branger D, Enjalbert A, Grisoli F, Jaquet P. Pit-1 gene expression in the human pituitary and pituitary adenomas. The Journal of Clinical Endocrinology and Metabolism. 79: 189-196. PMID 8027225 DOI: 10.1210/Jcem.79.1.8027225  0.352
1994 Bouillot P, Pellissier J, Devictor B, Graziani N, Bianco N, Grisoli F, Figarella-Branger D. Quantitative imaging of estrogen and progesterone receptors, estrogen-regulated protein, and growth fraction: immunocytochemical assays in 52 meningiomas: Correlation with clinical and morphological data Journal of Neurosurgery. 81: 765-773. PMID 7523635 DOI: 10.3171/Jns.1994.81.5.0765  0.325
1992 Figarella-Branger D, Gambarelli D, Perez-Castillo M, Gentet JC, Grisoli F, Pellissier JF. Ectopic intrapelvic medulloepithelioma: case Report Neuropathology and Applied Neurobiology. 18: 408-414. PMID 1528392 DOI: 10.1111/J.1365-2990.1992.Tb00802.X  0.31
1991 Figarella-Branger D, Gambarelli D, Dollo C, Devictor B, Perez-Castillo AM, Genitori L, Lena G, Choux M, Pellissier JF. Infratentorial ependymomas of childhood. Correlation between histological features, immunohistological phenotype, silver nucleolar organizer region staining values and post-operative survival in 16 cases. Acta Neuropathologica. 82: 208-16. PMID 1718129 DOI: 10.1007/Bf00294447  0.394
Show low-probability matches.